Prolonged SARS-CoV-2 RNA virus shedding and lymphopenia are hallmarks of COVID-19 in cancer patients with poor prognosis

4

Anne-Gaëlle GOUBET^{1,2,3}*, Agathe DUBUISSON^{2,3}*, Arthur GERAUD^{2,4,5}, François-5 Xavier DANLOS^{2,3}, Safae TERRISSE^{2,3}, Carolina ALVES COSTA SILVA^{2,3}, Damien 6 DRUBAY^{2,6,7}, Lea TOURI^{2,8}, Marion PICARD^{2,3,9}, Marine MAZZENGA^{2,3}, Aymeric 7 SILVIN^{2,3}, Garett DUNSMORE^{2,3}, Yacine HADDAD^{2,3}, Eugenie PIZZATO^{2,3}, Pierre LY^{2,3}, 8 Caroline FLAMENT^{2,3}, Cléa MELENOTTE^{2,3}, Eric SOLARY^{1,2,10,11} 9 Michaela GARCIA^{2,14}, FONTENAY^{12,13}. BALLEYGUIER^{2,14}. Corinne Gabriel 10 Nathalie LASSAU^{1,2,14,15}, Markus MAEURER¹⁶, Claudia GRAJEDA-IGLESIAS^{2,3,17,18}, Nitharsshini 11 NIRMALATHASAN^{2,17,18}, Fanny APRAHAMIAN^{2,17,18}, Sylvère DURAND^{2,17,18}, Oliver 12 KEPP^{17,18}, Gladys FERRERE^{2,3}, Cassandra THELEMAQUE^{2,3}, Imran LAHMAR^{2,3}, Jean-13 Eudes FAHRNER^{2,3}, Lydia MEZIANI^{2,19}, Abdelhakim AHMED-BELKACEM²⁰, Nadia SAÏDANI²¹, Bernard LA SCOLA^{22,23}, Didier RAOULT^{22,23}, Stéphanie GENTILE²⁴, 14 15 Sébastien CORTAREDONA^{23,25}, Giuseppe IPPOLITO²⁶, Benjamin LELOUVIER²⁷, Alain ROULET²⁷, Fabrice ANDRE^{1,2,4,28}, Fabrice BARLESI^{2,4,29}, Jean-Charles SORIA^{1,2}, Caroline PRADON^{2,30,31}, Emmanuelle GALLOIS^{2,32}, Fanny POMMERET^{2,4}, Emeline COLOMBA^{2,4}, 16 17 18 Florent GINHOUX^{33,34,35}, Suzanne KAZANDJIAN³⁶, Arielle ELKRIEF^{36,37}, Bertrand ROUTY^{37,38}, Makoto MIYARA³⁹, Guy GOROCHOV³⁹, Eric DEUTSCH^{1,2,19,40}, Laurence ALBIGES^{1,2,4}, Annabelle STOCLIN^{2,41}, Bertrand GACHOT^{2,42}, Anne FLORIN^{2,8}, Mansouria MERAD^{2,43}, Florian SCOTTE^{2,44}, Souad ASSAAD^{45,46,47}, Guido KROEMER^{2,17,18,48,49,50,51}, Jean-Yves BLAY^{45,46,47}, Aurélien MARABELLE^{2,3,4,5,52}, Frank GRISCELLI^{2,32,53,54,55}, 19 20 21 22 23 Laurence ZITVOGEL^{1,2,3,52}** & Lisa DEROSA^{1,2,3,4}**. 24

25

26 * Co-first authors have equally contributed to this work.

27 ** Co-last authors have equally contributed to this work.

28

²⁹ ¹Université Paris-Saclay, Faculté de Médecine, Le Kremlin-Bicêtre, France.

²Gustave Roussy Cancer Campus, Villejuif, France.

³Institut National de la Santé et de la Recherche Médicale, UMR1015, Gustave Roussy,
 Villejuif, France.

⁴Département d'Oncologie Médicale, Gustave Roussy, Villejuif, France.

⁵Département d'Innovation Thérapeutique et d'Essais Précoces, Gustave Roussy, Villejuif,
 France.

⁶Département de Biostatistique et d'Epidémiologie, Gustave Roussy, Université Paris-Saclay,

37 Villejuif, France.

³⁸ ⁷Institut National de la Santé et de la Recherche Médicale Oncostat, U1018, Equipe labellisée

39 par la Ligue Contre le Cancer, Gustave Roussy, Villejuif, France.

- 40 ⁸Médecine du travail, Gustave Roussy, Villejuif, France.
- ⁴¹ ⁹Institut Pasteur, Unit Biology and Genetics of the Bacterial Cell Wall, Paris, France; CNRS
- 42 UMR2001, Paris, France; INSERM, Equipe Avenir, Paris, France.
- ⁴³¹⁰Institut National de la Santé et de la Recherche Médicale, U1287, Gustave Roussy, Villejuif,

44 France.

- 45 ¹¹Département d'Hématologie, Gustave Roussy, Villejuif, France.
- 46 ¹²Université de Paris, Institut Cochin, Centre National de la Recherche Scientifique
- 47 UMR8104, Institut National de la Santé et de la Recherche Médicale U1016, Paris, France.

- ¹³Service d'hématologie biologique, Hôpital Cochin, Assistance Publique Hôpitaux de 48
- Paris.Centre-Université de Paris, Paris, France. 49
- ¹⁴Département d'Imagerie Médicale, Gustave Roussy, Villejuif, France. 50
- ¹⁵Biomaps, UMR1281, INSERM, CNRS, CEA, Université Paris Saclay 51
- ¹⁶Immunotherapy/Immunosurgery, Champalimaud foundation, Lisboa, Portugal. 52
- ¹⁷Centre de Recherche des Cordeliers, Equipe labellisée par la Ligue contre le cancer, 53
- Université de Paris, Sorbonne Université, Inserm U1138, Institut Universitaire de France, 54
- 55 Paris. France.
- ¹⁸Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Center, Université Paris 56 Saclay, Villejuif, France. 57
- ¹⁹Institut National de la Santé et de la Recherche Médicale, U1030, Gustave Roussy, Villejuif, 58 59 France.
- ²⁰Univ Paris Est Creteil, INSERM U955, IMRB, Creteil, France. 60
- ²¹Service de maladies infectieuses, Centre Hospitalier de Cornouaille, Quimper, France. 61
- ²²Aix-Marseille Université, Institut de Recherche pour le Développement, Assistance 62
- Publique Hôpitaux de Marseille, Microbes Evolution Phylogeny and Infections, Marseille, 63 64 France.
- ²³Institut Hospitalo-Universitaire Méditerranée Infection, Marseille, France. 65
- ²⁴Aix Marseille Univ, School of medicine La Timone Medical Campus, EA 3279: CEReSS -66
- Health Service Research and Quality of life Center, Marseille, France. 67
- ²⁵Aix VITROME. Marseille, Marseille IRD. AP-HM. 68 Université. SSA. France. 69
- ²⁶Scientific Direction, National Institute for Infectious Diseases Lazzaro Spallanzani, Rome, 70 71 Italy.
- ²⁷Vaiomer, Labège, France. 72
- ²⁸Institut National de la Santé et de la Recherche Médicale, U981, Gustave Roussy, Villejuif, 73 74 France.
- ²⁹Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France. 75
- ³⁰Centre de ressources biologiques, ET-EXTRA, Gustave Roussy, Villejuif, France. 76
- ³¹Département de Biologie Médicale et Pathologie Médicales, service de biochimie, Gustave 77
- 78 Roussy, Villejuif, France.
- ³²Département de Biologie Médicale et Pathologie Médicales, service de microbiologie. 79 Gustave Roussy, Villejuif, France. 80
- ³³Singapore Immunology Network, Agency for Science, Technology and Research 81 82 (A*STAR), Singapore.
- ³⁴Shanghai Institute of Immunology, Shangai, China. 83
- ³⁵Translational Immunology Institute, SingHealth Duke-NUS Academic Medical Center, 84 85 Singapore.
- ³⁶Cedar's Cancer Center, McGill University Healthcare Centre, Montreal, QC, Canada. 86
- ³⁷Centre de recherche du Centre hospitalier de l'Université de Montréal (CRCHUM), 87
- 88 Montreal, QC, Canada.
- ³⁸Department of Hematology-Oncology, Centre hospitalier de l'Université de Montréal. 89 90 Montreal, OC, Canada.
- ³⁹Institut National de la Santé et de la Recherche Médicale, U1135, Centre d'Immunologie et 91
- 92 des Maladies Infectieuses, Hôpital Pitié-Salpêtrière, Assistance Publique – Hôpitaux de Paris, 93 Paris, France.
- ⁴⁰Département de Radiothérapie, Gustave Roussy, Villejuif, France. 94
- ⁴¹Service de Réanimation Médicale, Gustave Roussy, Villejuif, France, 95
- ⁴²Service de Pathologie Infectieuse, Gustave Roussy, Villejuif, France. 96
- ⁴³Service de médecine aigue d'urgence en cancérologie, Gustave Roussy, Villejuif, France. 97

- 98 ⁴⁴Département Interdisciplinaire d'Organisation des Parcours Patients, Gustave Roussy,
- 99 Villejuif, France.
- 100 ⁴⁵Centre Léon Bérard, Lyon, France.
- ⁴⁶Université Claude Bernard, Lyon, France.
- ⁴⁷Unicancer, Paris, France.
- 103 ⁴⁸Université de Paris, Paris, France.
- ⁴⁹Department of Women's and Children's Health, Karolinska Institute, Karolinska University
- 105 Hospital, Stockholm, Sweden.
- ⁵⁰Pôle de Biologie, Hôpital Européen George Pompidou, Assistance Publique Hôpitaux de
- 107 Paris, Paris, France.
- ⁵¹Suzhou Institute for Systems Biology, Chinese Academy of Medical Sciences, Suzhou,
 China.
- ⁵²Center of clinical investigations BIOTHERIS, Gustave Roussy, Villejuif, France.
- ⁵³Institut National de la Santé et de la Recherche Médicale UMR935/UA9, Université Paris-
- 112 Saclay, Villejuif, France.
- ⁵⁴INGESTEM National IPSC Infrastructure, Université de Paris-Saclay, Villejuif, France.
- ⁵⁵Université de Paris, Faculté des Sciences Pharmaceutiques et Biologiques, Paris, France.
- 115
- 116 Corresponding authors:
- 117 Lisa DEROSA MD, PhD
- 118 Department of Medical Oncology
- 119 Head of Clinics of the Microbiome
- 120 University Paris Saclay,
- 121 Gustave Roussy Cancer Center
- 122 114 rue Edouard Vaillant, 94805 Villejuif Cedex, France
- 123 Telephone: +33 1 42 11 24 51
- 124 E-mail: lisa.derosa@gustaveroussy.fr
- 125
- 126 and Laurence ZITVOGEL, MD, PhD, Full Professor
- 127 University Paris Saclay,
- 128 Gustave Roussy Cancer Center,
- 129 114 rue Edouard Vaillant,
- 130 94805 Villejuif Cedex, France
- 131 Telephone: +33 1 42 11 50 41
- 132 E-mail: laurence.zitvogel@gustaveroussy.fr
- 133
- 134 Keywords: cancer, COVID-19, lymphopenia, immunopathology
- 135
- 136

Abbreviations in alphabetic order: ACE2: Angiotensin-Converting Enzyme 2; CD: cluster 137 138 of differentiation; cMo: classical monocytes; COVID-19: severe coronavirus infectious 139 disease 2019; Ct: Cycle threshold; CR: Clinical Routine; CXCR5: C-X-C chemokine receptor 140 type 5; ECOG: Eastern Cooperative Oncology Group performance status; EM: effector 141 memory cells; Eomes: eomesodermin; FC: fold change; FasL: Fas ligand; GzB: granzyme B; 142 HCW: health care worker; ICOS: Inducible T-cell co-stimulator; ICU: intensive care unit; 143 IFN: Interferon; Ig: Immunoglobulin; IL: interleukin; LVS: long term viral RNA shedding; 144 NK: Natural killer; ; non-cMo: non classical monocytes; NSM: Non-switch Memory; Orf1b: 145 replicase open reading frame 1b; PD: progressive disease; PD-1: programmed cell death 1; 146 PMN: polymorphonuclear cells; RBD: receptor-binding domain; RdRP: RNA-dependent 147 RNA polymerase; RNA: ribonucleic acid; rIL-7: recombinant interleukin 7; RT-qPCR: 148 quantitative reverse transcription-polymerase chain reaction; SARS-CoV-2: severe acute 149 respiratory syndrome coronavirus 2; SD: stable disease; SVS: short term viral RNA shedding; 150 Tc1: cytotoxic T lymphocytes; TCF-1: Transcription factor 1; TFH: T follicular helper cells; 151 TR: Translational Research.

154 Abstract

155

156 Patients with cancer are at higher risk of severe coronavirus infectious disease 2019 (COVID-19), but the mechanisms underlying virus-host interactions during cancer 157 158 therapies remain elusive. When comparing nasopharyngeal swabs from cancer and non-159 cancer patients for RT-qPCR cycle thresholds measuring acute respiratory syndrome coronavirus-2 (SARS-CoV-2) in 1063 patients (58% with cancer, 89% COVID-19⁺), we 160 found that malignant disease favors the magnitude and duration of viral RNA shedding 161 162 concomitant with prolonged serum elevations of type 1 IFN that anticorrelated with 163 anti-RBD IgG antibodies. Chronic viral RNA carriers exhibited the typical immunopathology of severe COVID-19 at the early phase of infection including 164 165 circulation of immature neutrophils, depletion of non-conventional monocytes and a general lymphopenia that, however, was accompanied by a rise in plasmablasts, 166 activated follicular T helper cells, and non-naive Granzyme B⁺FasL⁺, Eomes^{high}TCF-167 1^{high}, PD-1⁺CD8⁺ Tc1 cells. Virus-induced lymphopenia worsened cancer-associated 168 lymphocyte loss, and low lymphocyte counts correlated with chronic SARS-CoV-2 RNA 169 170 shedding, COVID-19 severity and a higher risk of cancer-related death in the first and 171 second surge of the pandemic. Lymphocyte loss correlated with significant changes in 172 metabolites from the polyamine and biliary salt pathways as well as increased blood 173 DNA from Enterobacteriaceae and Micrococcaceae gut family members in long term 174 viral carriers. We surmise that cancer therapies may exacerbate the paradoxical 175 association between lymphopenia and COVID-19-related immunopathology, and that 176 the prevention of COVID-19-induced lymphocyte loss may reduce cancer-associated 177 death.

178

179

180

182 Introduction

183

184

185 Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel beta-186 coronavirus that has caused a worldwide pandemic of the human respiratory illness COVID-187 19, resulting in a severe threat to public health and safety worldwide. Because of age, gender, 188 cancer-associated risk factors, metabolic syndrome and side effects induced by their specific 189 therapies (such as cardiomyopathy, systemic immunosuppression and cellular senescence), 190 cancer patients appear more vulnerable to severe infection than individuals without cancer 191 (Derosa et al., 2020). Indeed, a high hospitalization and mortality rates of SARS-CoV-2 192 infection were heralded in patients with malignancy in several studies across distinct 193 geographical sites (Albiges et al., 2020; Assaad et al., 2020; Luo et al., 2020; Rugge et al., 194 2020). Cancer types, performance status and stage are additional risk factors for severe 195 COVID-19 in this patient population. Patients with hematological, lung and breast cancer 196 have been reported to be more susceptible to hospitalization or death due to COVID-19 as 197 compared to patients with other malignancies (Garassino et al., 2020; Luo et al., 2020; 198 Martín-Moro et al., 2020; Passamonti et al., 2020; Rugge et al., 2020). Patients diagnosed 199 with metastatic cancers are more vulnerable to severe forms of COVID-19 than individuals 200 with localized malignancies (Robilotti et al., 2020). Recent (<3 months) cancer treatments 201 including surgery, chemotherapy and immunotherapy independently contribute to worsen the 202 prognosis of COVID-19 among patients with malignant disease (Albiges et al., 2020; Dai et 203 al., 2020; Luo et al., 2020; Passamonti et al., 2020; Q et al., 2020; Robilotti et al., 2020).

204 Here we explored several independent cohorts of cancer patients diagnosed with 205 COVID-19 (1063 patients, 58% with cancer) during the first surge of the pandemic to analyze 206 the dynamics between host (blood immunology, metabolism, metagenomics) and viral 207 parameters and validated the most clinically relevant findings in the second surge of the 208 pandemic. We concluded that virus-induced or -associated lymphopenia that coincided with T 209 cell exhaustion, abnormalities in polyamine and biliary salt pathways and circulation of 210 Enterobacteriaceae and Micrococcaceae bacterial DNA, is a dismal prognosis factor in cancer 211 patients, likely participating in the vicious circle of immunosuppression-associated chronic 212 virus shedding.

214 **Results**

215

Prolonged viral shedding and higher viral loads in cancer patients compared with cancer free COVID-19⁺ patients

219 To explore the clinical significance of viral and/or immunological parameters in cancer 220 patients, we gathered the data from electronic clinical files from various cancer centers or 221 general hospitals across France and Canada, in order to monitor the magnitude and duration 222 of virus RNA shedding in nasopharyngeal swabs according to cancer (versus health care 223 workers (HCW) or COVID-19⁺ cancer free individuals), tumor types (hematological versus 224 solid malignancies) and staging (localized, locally advanced, metastatic diseases) (Figure 1A). 225 First, we conducted a prospective epidemiological study named Cancer_FR1_Translational 226 Research (TR) at Gustave Roussy, Villejuif, France, during the first surge of the COVID-19 227 pandemic (from April 10, 2020 to May 11, 2020, NCT04341207) to evaluate the prevalence 228 and severity of COVID-19 in all adult patients under treatment or recently treated for solid 229 tumors or hematological malignancies (Figure S1, Table S1). Our secondary endpoint was the 230 identification of viral, immunological, metabolic and metagenomics blood predictors of 231 severe complications among cancer patients. Clinical characteristics were collected from 232 electronic medical records (Table S1). Nasopharyngeal samples were serially collected at 233 every hospital visit motivated by the cancer management or any symptomatology related to 234 seasonal flu or COVID-19 and transferred to the virology laboratory for SARS-CoV-2-235 specific quantitative reverse transcription-PCR (RT-qPCR) testing. Out of 473 patients 236 enrolled in Cancer_FR1_TR, 53 (11%) were diagnosed with COVID-19 by RT-qPCR, and 237 this diagnosis was corroborated by a specific serology in 87% cases (Figure S1A). Among the 238 52 patients evaluable for translational research, 37% were males, 60% suffered from at least 239 one of the co-morbidities associated with coronavirus pandemic, such as hypertension (58%) 240 or obesity (21%) (Table S1). Seventy seven percent had an ECOG performance status of 0-1 241 at the time of nasopharyngeal sampling. Twenty one percent of COVID-19 positive cancer 242 patients did not report any symptom of infection, 61% required hospital admission (for any 243 cause or because of COVID-19 aggravation within 28 days after diagnosis) and 11% a 244 transfer to intensive care unit (ICU), culminating with cancer death in 7% of the cases (from 245 undetermined cause, no systematic necropsy) (Figure S1B-G, Table S1). Among patients with 246 cancer diagnosed with COVID-19, 20% were followed up for hematological (as opposed to 247 solid) malignancies and developed more severe symptoms of infection (Figure S1B-G, Table

S1). In the Cancer_FR1_TR study, 33%, 21% and 46% presented with localized, locally
advanced and metastatic disease, respectively that were equally susceptible to severe COVID-

250 19 (Figure S1F-G).

251 Given that cycle threshold (Ct) values of the first RT-qPCR test may be correlated with the 252 clinical characteristics of the patients (Shlomai et al., 2020; Westblade et al., 2020), we 253 performed a longitudinal follow-up of Ct values by RT-qPCR. We targeted several genes 254 coding for the envelope, the nucleocapsid and/or the replication-transcription complex (RdRP, 255 Orf1a, subgenomic RNA of the SARS-CoV-2 (Corman et al., 2020)(Wölfel et al., 2020)) to 256 assess the duration of the nasopharyngeal SARS-CoV-2 RNA shedding, starting at COVID-257 19 diagnosis for up to 6 months as per-protocol indications (Figure S2A). The duration of 258 viral shedding was defined as the number of days from the first positive to the first negative 259 RT-qPCR, after longitudinal monitoring with an interval inferior to 40 days, to reduce bias in 260 viral shedding estimation. This time lapse of 40 days corresponded to the median of SARS-261 CoV-2 virus carriage in the cancer population (Figure 1B-C, Table S1). In parallel, a similar 262 and systematic COVID-19 protocol with longitudinal RT-qPCR testing was applied to health 263 care workers (HCW) at Gustave Roussy. Health care workers had a mean age of 35 years 264 (range: 19-61), were mostly females (male versus female: 13% versus 87%), and presented 265 with one or two co-morbidities in 27% and 4%, respectively, thereby significantly diverging 266 from the cancer population diagnosed with COVID-19. Starting from 50 COVID-19 positive 267 cancer patients and 100 HCW, we conducted RT-qPCR in 210 and 200 nasopharyngeal 268 swabs, respectively (Figure S2). However, applying the exclusion criteria detailed in Figure 269 S2, we could compare the median length of SARS-CoV-2 RNA detection in 35 cancer 270 patients (Cancer_FR1_TR) and 45 HCW using 168 and 118 samples, respectively. Patients 271 with cancer exhibited prolonged nasopharyngeal RNA virus shedding (Figure 1B, median of 272 40 days (range: 6-137) for patients with cancer compared to 21 days (range: 7-53) for HCW, 273 Figure 1C, log-rank test *p*-value <0.0001). This difference persisted after adjusting for age, 274 gender and co-morbidities (Cox multivariate analysis, adjusted hazard ratio [95% confidence 275 interval] =2.88 [1.42;5/85], p=0.00291, Figure 1C). To further validate the differences 276 observed in the duration of viral RNA shedding between Cancer_FR1_TR and HCW, we 277 analyzed another cohort of patients diagnosed with COVID-19 in a general hospital from 278 Southern France and paired - in a case-control study - 175 cancer patients (with a history of 279 cancer or currently treated with cancer (Table S1)) with 350 cancer free individuals based on 280 age, gender, comorbidities and COVID-19 severity (FR2_Case-Control, Cancer and Non-281 Cancer) (Figure 1A, Table S1). Here again, there was a prolonged length of RT-qPCR

282 positivity in cancer individuals compared with cancer free COVID-19 patients (8 days versus 283 6 days, log-rank test p-value, p=0.03), taking into account that >70% were treated with 284 hydroxychloroquine and azithromycine, a combination regimen reducing viral shedding 285 (Lagier et al., 2020). Moreover, the proportion of patients with a viral shedding above 16 days (corresponding to the 90th percentile of the viral shedding in cancer-free patients) was higher 286 287 in cancer patients (Figure 1D, p < 0.0015). A second independent validation was achieved in a 288 third series of 66 patients with cancer extracted from a cohort of 252 cancer individuals living 289 in Canada and diagnosed with COVID-19 (Cancer_CA), for whom a longitudinal SARS-290 CoV-2-specific RT-qPCR (using *Orf1* and *E* gene probe sets (Boutin et al., 2020)) follow-up 291 had been carried out (Elkrief et al., 2020) (Figure 1A, Table S1). Here again, we observed that 292 26% of cancer patients were still PCR positive after 40 days from diagnosis by RT-qPCR 293 (Figure 1E). Such a long term PCR detection of viral RNA could indicate stable subgenomic 294 RNA contained within double membrane vesicles or presence of a replicative mucosal viral 295 strain. Hence, we confirmed in three independent series of cancer patients a prolongation of 296 RNA virus shedding previously described in case reports in hematological or immuno-297 compromised patients (Avanzato et al., 2020; Aydillo et al., 2020; Choi et al., 2020; 298 Helleberg et al., 2020).

299

300 Hence, we focused on the differential characteristics of cancer patients presenting with Long 301 term Viral RNA Shedding (LVS), defined by a positive RT-qPCR duration \geq 40 days (median 302 of RT-qPCR duration in Cancer FR1 TR (Figure 1C)), compared to those experiencing Short 303 term Viral RNA Shedding (SVS), defined by a positive RT-qPCR duration < 40 days 304 henceforth (Table S1). The increased susceptibility to develop a LVS was independent of 305 initial symptomatology, observed in 33% of Canadian (CA) to 40% of French (FR1_TR) 306 asymptomatic and 27% (CA) to 56% (FR1_TR) of symptomatic cancer patients (Figure 1F). 307 There was a higher propensity to LVS in hematological malignancies compared to solid 308 cancers (86% versus 43%, respectively (p=0.04, Figure 1G, Table S1) and in advanced 309 disease (p=0.011) in FR1_TR cohort (Figure 1H, Table S1) but less so, in the CA cohort. 310 Importantly, the LVS phenotype was associated with COVID-19 severity, notably an 311 increased risk to develop a moderate form (defined by thoracic CT scan, hospitalization and 312 oxygen requirement < 9 L/min) in Cancer_FR1_TR (p=0.032) (Figure 1I). This trend was 313 confirmed in a third series of French patients from the clinical routine (CR) managed outside 314 the translational ancillary study at Gustave Roussy (called henceforth "Cancer_FR1_CR"; 315 Table S1, Figure S3), where 20% cancer patients were diagnosed with LVS and exhibited

more severe COVID-19 infections (Figure 1I, p=0.011). Again, the hospitalization rates and transfer to intensive care units were increased in LVS compared with SVS patients in Cancer_FR1_TR (p=0.0018, Table S1) and Cancer_FR2, respectively (p=0.02, Table S1). Finally, the FR2 and Canadian series of LVS cancer patients also tended to exhibit more severe manifestations of COVID-19 compared with SVS Canadian cancer patients (Figure 1I, bottom).

322

323 Of note, the duration of viral RNA shedding correlated with "viral load", *i.e* Ct values 324 at diagnosis, in that cancer patients with LVS experienced lower Ct values at diagnosis than 325 SVS cancer patients in most cohorts for which the data were available (Figure 1J). 326 Importantly, cancer patients doomed to develop LVS presented with lower Ct values at 327 diagnosis than those prone to become SVS in Cancer_FR1 and Cancer_FR2 cohorts (Figure 328 1K). The dynamic course of the infection was significantly different in SVS and LVS, as 329 indicated by the Ct values that remained high for a prolonged period of time in LVS patients 330 compared with SVS (Figure 1L). Of note, Ct values at disease onset were significantly 331 anticorrelated with duration of viral RNA shedding in cancer patients using either N or 332 Orflab/RdRP gene-specific probe sets.

333 The redundancy analysis (RDA) is an extension of the principal component analysis 334 (PCA) aimed at identifying viral components which depend on other known covariates such 335 as clinical parameters. RDA revealed that, within 30 days from diagnosis, 18% of the 336 variance of the biological parameters are explained by 10 components adjusted for the major 337 clinical parameters for COVID-19 in Cancer FR1 TR (Figure 1M). These components were 338 mainly influenced by the virus shedding (SVS versus COVID-19 negative, p=0.037; LVS 339 versus COVID-19 negative, p=0.0010), COVID severity (mild versus COVID-19 negative, 340 p=0.0030; moderate versus COVID-19 negative, p=0.0574; severe versus COVID-19 341 negative, p not computable), age (p=0.0514), hematological rather than solid malignancy 342 (hematological versus solid, p=0.001), metastatic status (p=0.0059), and Ct values at 343 diagnosis (> 25 versus < 25, p=0.0738). As outlined in Table S1, LVS patients tended to be 344 older (66 versus 56 years old, p=0.08), more metastatic (72% versus 29%, p=0.01), and 345 experienced increased hospitalization rates (83% versus 23%, p<0.001) than SVS cancer 346 patients in the Cancer_FR1_TR cohort.

348

Immunological hallmarks of long-term virus carriers at diagnosis

349

350 Intrigued by these findings, we addressed the question as to whether and how 351 prolonged viral RNA shedding would impact on Cancer_FR1_TR patients with respect to 352 COVID-19-related immunological alterations previously reported for cancer-free infected 353 individuals (Arunachalam et al., 2020; Chua et al., 2020; Kaneko et al., 2020; Laing et al., 354 2020; Mathew et al., 2020; Silvin et al., 2020; Takahashi et al., 2020). More than 80 355 phenotypic markers were quantified on circulating leukocytes by means of high dimensional 356 spectral flow cytometry, complemented by multiplex ELISAs to detect serum chemokines, 357 cytokines and growth factors. These parameters were recorded within or after the first 20 days 358 of inclusion in the Cancer_FR1_TR protocol, for 25 COVID-19⁺ cancer patients that were 359 divided into LVS versus SVS subgroups, in comparison to 43 COVID-19 negative cancer 360 patients ("controls" or "Ctls") matched for age, gender, co-morbidities, cancer types and 361 tumor extension (Table S2). Asymptomatic individuals and cancer patients enrolled at the 362 recovery phase of COVID-19 (meaning that they became PCR negative) were analyzed 363 separately. Within the first 20 days from diagnosis, LVS presented increased proportions of 364 monocytes among circulating leukocytes (Figure S4A, left panel), and a parallel drop in CD169⁻HLA-DR⁺ within conventional monocytes (Figure S4A, middle panel) and in non-365 conventional monocytes (CD16⁺CD14^{low/-}, Figure S3A right panel) compared to SVS, 366 367 cancer controls, asymptomatic or recovered patients, as reported (Carvelli et al., 2020; Silvin et al., 2020). Polymorphonuclear cells (PMN) tended to increase in LVS, specifically 368 immature CD101^{+/-}CD10^{+/-}CD16⁻ neutrophils, compared with SVS, convalescent and 369 370 controls (Figure 2A-B, upper and lower panels, Figure S4B).

371

372 Importantly, the most significant phenotypic traits distinguishing LVS from SVS 373 featured among the reported hallmarks of severe COVID-19 in cancer-free subjects 374 (Arunachalam et al., 2020; Chua et al., 2020; Kaneko et al., 2020; Laing et al., 2020; Mathew 375 et al., 2020; Silvin et al., 2020; Takahashi et al., 2020) (Figure 2A). In accordance with the 376 reported defects in germinal center formation in secondary lymphoid organs of severe COVID-19 (Kaneko et al., 2020), LVS cancer patients exhibited increased recirculation of 377 activated CXCR5⁺PD-1^{high} CD4⁺ follicular T helper cells (TFH) expressing ICOS and CD38 378 (Figure 2C, left panel), as well as a marked rise in plasmablasts (defined as CD19^{low} CD27^{hi} 379

CD38^{hi}) at the expense of transitional B (CD24⁺CD38^{hi}CD19⁺) and double negative B cells 380 (IgD^{CD27}CD19⁺) (Figure 2C right panel, Figure S4C, Figure 2D). As indicated in the 381 Volcano plot in Figure 2A, immature PMN and double negative B cells were among the most 382 383 significant immunological features, positively and negatively predicting LVS, respectively 384 (Figure 2B bottom panel and Figure 2D right panel). LVS coincided with prolonged systemic 385 release of, and exposure to, type 1 IFN above levels measured in SVS, controls and recovered 386 individuals (Figure 2E). Type 1 IFN levels anticorrelated with titers of neutralizing anti-S1 387 RBD antibodies (Figure 2F). This landscape of immune profiling was corroborated by non-388 supervised hierarchical clustering of innate and cognate immunotypes and serum cytokine 389 concentrations analyzed within 30 days from diagnosis. This method allowed to segregate a 390 small cluster of individuals characterized by low Ct values (< 25), and moderate/severe 391 complications of COVID-19, that included metastatic cancer carriers with LVS or SVS 392 (Figure S5). This cluster was separated from the others by typical signs of viral infection, including abundant circulating CD38⁺HLA-DR⁺CD8⁺T cells, plasmablasts, activated TFH 393 394 cells and high serum IFNa2a levels (Figure S5). Likewise, while many inflammatory 395 cytokines, chemokines or alarmins (such as IFNy, CXCL10, IL-4, IL-6 and calprotectin) were 396 elevated in symptomatic COVID-19 individuals compared with controls, asymptomatic and 397 recovered patients, none of them could predict LVS, except a drop in the IFN γ /IFN α 2a and 398 CCL11/CXCL10 ratios whose significance remains unclear (p=0.016 and p=0.0019, 399 respectively) (Figure S4D-I). Interestingly, innate and cognate immunotypes performed in 400 convalescent patients and controls segregated at random in the non-supervised hierarchical 401 clustering (Figure S6).

402 Altogether, the high dimensional flow cytometry of blood immune subsets indicated 403 that LVS cancer patients harbored the immunological hallmarks of severe COVID-19 at 404 diagnosis.

405

406 Virus-associated lymphopenia predicted shorter overall survival in the first and second 407 surge of the pandemic

408

409 Lymphocyte loss is a feature of severe COVID-19 in non-cancer patients (Laing et al.,
410 2020; Mathew et al., 2020). Not surprisingly, blood absolute lymphocyte counts (ALC) at
411 diagnosis anticorrelated with the duration of PCR positivity in Cancer_FR1_TR and

412 Cancer FR1 CR cohorts (Figure 3A). However, although the ALC before the COVID-19 413 pandemic (blood drawn from December 2019 to mid-March 2020) were already somewhat 414 lower in LVS than in SVS cancer patients, the ALC during the outbreak dramatically dropped 415 in cancer patients doomed to develop LVS (in both Cancer_FR1_TR and Cancer_FR1_CR 416 cohorts), more so than in individuals prone to SVS (Figure 3B, left panel). The extent in ALC 417 reduction was more severe in patients presenting LVS than SVS (Figure 3C). Of note, ALC 418 recovered in both patient groups regardless of the LVS/SVS status, supporting the contention 419 that reduced ALC at COVID-19 diagnosis is induced by the virus rather than by the cancer 420 (Figure 3B, left panel). In accord with the finding that LVS correlates with high viral load at 421 symptom onset (Figure 1J-K), higher viral loads at diagnosis were associated with a 422 pronounced COVID19-associated lymphopenia (Figure 3B, right panel).

423 We next assessed the clinical significance of the interaction between Ct values, ALC 424 and cancer patient survival in 110 cancer patients with COVID-19 (Discovery cohort (first 425 surge of the pandemic) including 84 patients from Cancer_FR1 treated at Gustave Roussy and 426 26 patients from Cancer FR3 treated at Léon Bérard Cancer Center in Lyon, France) (Figure 427 3D, Table 1). Cox logistic regression analyses and Kaplan Meier survival curves were 428 performed after stratification of the patients according to both, Ct and ALC values at 429 diagnosis. The cut-off for the Ct value was 25 and corresponded to the median of the whole 430 cohort FR1+FR3, which coincided with the threshold at which live virus particles can be isolated in 70% of the cases (Jaafar et al., 2020). The cut-off value for ALC was the median 431 found in patients with high viral load (Ct < 25) at diagnosis (ALC=800/mm³). ALC combined 432 433 with Ct values predicted cancer-related overall survival in univariate analyses across all cancer stages (local, locally advanced or metastatic) (Figure 3D, Table 1). While patients 434 presenting with ALC > $800/\text{mm}^3$ and low viral load (Ct > 25) exhibited prolonged survival, a 435 436 dismal prognosis affected 21% of them (23/110) who presented both deep lymphopenia (ALC $< 800/\text{mm}^3$) and high viral loads (Ct < 25) at diagnosis (Figure 3D) culminating in 40% 437 438 deaths at 3 months. All 4 groups were comparable in terms of age, gender, co-morbidities, 439 cancer type or staging (Table 1). Multivariate Cox analysis stratified for the cohort origin and 440 adjusted for age (hazard ratio [95% confidence interval]=1.042 [1.013; 1.072], p=0.0043), 441 ECOG performance status (4.547 [1.845; 11.206], p=0.0001), gender (1.668 [0.775; 3.588], 442 p=0.1907) and metastatic status and hematological malignancies (2.747 [1.090; 6.923], 443 p=0.0322) confirmed a continuous decrease of risk with the increase of the Ct value (0.841) 444 [0.776; 0.911], p=0.00002) and the increase of the ALC (0.282 [0.119; 0.672], p=0.0043)

(Figure 3E). Of note, treatment retardation could not explain the high mortality of patientspresenting with a high viral load and low ALC (Table 1).

447 We confirmed these predictors (ALC < 800 & Ct < 25) of poor survival during the second surge of the pandemic (between May 5th, 2020 to November 25th, 2020) in 116 new 448 449 COVID-19 cancer patients ("Validation", Cancer FR1 and Cancer FR3, Figure 1A). Here 450 again, the subset of patients with ALC < 800 & Ct < 25 (n=38/116, 32.7%) exhibited the most 451 reduced overall survival compared to the other groups with > 40% deaths at 50 days (Figure 452 3F). Of note, the reduced survival rate in the subset of patients defined by ALC < 800 & Ct <453 25 was not a peculiarity of hematological malignancies (characterized by therapy-induced B 454 cell depletion) since it was also observed in patients with solid neoplasia (Figure S7).

In conclusion, it appears that uncontrolled viral infection capable of compromising the number and function of circulating lymphocytes predicts lethal outcome of patients with a malignant disease.

458

459 Immunological, metabolic and metagenomic parameters associated with virus induced460 lymphocyte loss

461

Multiple and non-exclusive mechanisms could account for virus-associated lymphopenia (Arunachalam et al., 2020; Campbell et al., 2020; Mathew et al., 2020; Moole and Papireddypalli, 2020; Sheng et al., 2017; Song et al., 2020). To further investigate this deleterious virus-induced lymphocyte loss, we searched for the most robust correlates between ALC and immunological, metabolic or pathogenic cues in the Cancer_FR_TR cohort as well as non-cancer COVID-19 patients that we previously reported (Silvin et al., 2020).

468 Firstly, the Spearman correlation matrix of the main immunological and serum 469 markers monitored at the peak of disease (within the first 20 days of disease onset) indicated 470 close interconnections between lymphocyte proportions and their subsets within leukocytes 471 (Figure 4A). Lymphopenia, which is a prominent feature of COVID-19 and a hallmark of 472 severe infection, distinguished LVS from SVS or asymptomatic individuals (Figure S8A-B), 473 as exemplified for the proportion of B lymphocytes among total CD45⁺ leukocytes after 20 474 days of symptoms. As reported (Mathew et al., 2020), the transitional differentiation of naive into effector/memory T cells co-expressing CD38⁺HLA-DR⁺ among CD8⁺T cells is a 475 476 hallmark of COVID-19 that persisted in LVS compared to controls and SVS (p=0.002 and 477 p=0.012) (Figure S7C, right panel). In particular, the most compelling LVS-associated T cell

478 subpopulation that expanded in the context of lymphopenia was the non-naive (non- $CD45RA^{+}CD27^{+}$) $CD8^{+}$ T subset expressing an activation/exhaustion phenotype 479 480 characterized by early and sustained expression of PD-1 (Figure 4B), Eomes, Granzyme B, 481 TCF-1 including the pro-apoptotic marker CD95-L (FasL) (Figure 4C-D left panel). The abundance of these non-naïve exhausted $PD-1^{+}CD8^{+}$ Tc1 cells positively correlated with the 482 483 duration of SARS-CoV-2 specific RT-qPCR positivity (Figure 4B, bottom panel and Figure 484 4D, right panel) and may explain, at least partly, the reduced fitness and half-life of peripheral 485 lymphocytes.

486 Secondly, we performed the serum metabolome determined by untargeted and targeted 487 mass spectrometry-based metabolomics analyzing more than 221 metabolites in 31 cancer 488 patients from Cancer_FR1_TR, as well as in a previously described cohort of 66 cancer-free 489 COVID-19⁺ patients for validation (Silvin et al., 2020). The non-supervised hierarchical 490 clustering of the serum metabolome clearly contrasted LVS from LVS patients (Figure S9). 491 The Volcano plot aimed at identifying significant differences between LVS and SVS patients 492 pointed out the biliary salt metabolic pathway segregating SVS from LVS serum (Figure 5A), 493 previously described to have biological significance for lymphocyte fitness and maintenance 494 (Campbell et al., 2020; Moole and Papireddypalli, 2020; Sheng et al., 2017; Song et al., 495 2020). Secondary biliary acids (such as the murideoxycholic acid (muri-DOC) (Figure 5B, 496 left panel) and the DOC (Figure 5C)) were decreased in LVS compared with SVS and 497 controls and correlated with lower ALC in cancer patients (Figure 5B, right panels) or severe 498 COVID-19 (Figure 5D). Similarly, two other derivatives of DOC (hyo-DOC, urso-DOC) 499 were decreased in LVS (compared to controls and SVS, Figure S10A-B, left panels) and were 500 associated with lymphocyte loss (Figure S10A and S10B, right panels).

501 Another metabolic pathway pertaining to polyamines with high biological significance for 502 age-related immunosenescence (Alsaleh et al., 2020; Puleston et al., 2014; Zhang et al., 2019) 503 was also strongly associated with the duration of RT-qPCR positivity, ALC and disease 504 severity (Figure 5E-G, Figure S9). In particular, the N1, N8-diacetylspermidine that 505 anticorrelated with ALC (Figure 5F, right panel) increased in the serum of LVS patients (but 506 not SVS, Figure 5F, left panel), in accordance with its marked rise in severe COVID-19 in 507 cancer-free individuals (Figure 5G, left panel) where high levels coincided with the 508 lymphocyte drop (Figure 5G, right panel). Of note, the tryptophane/kynurenine or lactic acid 509 metabolites were not relevant in our study (Figure 5A, Figure S9).

510 Thirdly, endotoxemia was shown to correlate with the cytokine storm during COVID-511 19 (Arunachalam et al., 2020) and might cause activation-induced lymphocyte cell death. 512 Assuming that the gut permeability could be altered during COVID-19-associated intestinal 513 dysbiosis (Yeoh et al., 2021), we studied the circulating microbial populations associated with 514 whole leukocytes by sequencing blood rDNA using next-generation sequencing of V3-V4 515 variable regions of the 16S rRNA bacterial gene as previously described (Païssé et al., 2016). 516 Although we failed to observe significant quantitative differences in blood bacterial load 517 between SVS (n=14) and LVS (n=15) patients, the linear discriminant analysis effect size 518 indicated significant taxonomic differences in the bacteria family members between the two 519 groups (Figure 6A-B). The DNA from Enterobacteriaceae (mainly composed of Escherichia 520 Shigella genus) was overrepresented in leukocytes of LVS compared with SVS patients 521 (Figure 6A-B, C left panel). The circulating Enterobacteriaceae-related DNA markedly 522 anticorrelated with CCL22 (a hallmark of SVS, Figure 2A), but was strongly associated with 523 the increase of exhausted CD8⁺ T lymphocytes (Figure 6D-E). There was a trend for an 524 increase in the relative abundance of Micrococcaceae in the blood leukocytes of LVS that was 525 confirmed in cancer patients with dismal prognosis (ALC < 800 & Ct < 25) (Figure 6F-G-H). 526 Overall, we conclude that virus-associated lymphopenia may result for complementary

527

528

529 530

531 **Discussion**

or coordinated orthogonal disorders.

532

533 To interrogate viral-host interactions during the COVID-19 pandemic in cancer 534 patients, we studied 1106 patients, among them 59% were cancer bearers 535 (FR1+FR2+FR3+CA), and 1063 COVID-19 positive (Figure 1A). We used high dimensional 536 flow cytometry to perform deep immune profiling of innate, B and T cells and measurements 537 of 51 soluble markers, with temporal analysis of immune changes during infection in one 538 cohort that was further explored by blood metabolomics and metagenomics. This longitudinal 539 immune analysis was linked to virologic and oncological data (Figure S5-S6). Using this 540 approach, we made several intriguing observations.

541

542 First, 51%, 20% and 26% of cancer patients in FR1_TR, FR1_CR and CA, 543 respectively, still shed SARS-CoV-2 RNA after day 40 from symptoms onset (*versus* 2% in

544 HCW), correlating with high viral loads (Ct values < 25) at diagnosis. Indeed, isolation of 545 replication-competent viral strains between 10 and 20 days after symptom onset has been 546 documented in some persons with severe COVID-19, mostly in immunocompromised cases 547 (Kampen et al., 2020). However, about 90% of their specimens no longer yielded replication-548 competent viruses after day 15 from symptom onset (Ge et al., 2020; Li et al., 2020). 549 Prolonged shedding of influenza, parainfluenza, rhinovirus, seasonal coronavirus and 550 respiratory syncytial virus has previously been detected in immunosuppressed patients (El 551 Ramahi and Freifeld, 2019; Geis et al., 2013; Lehners et al., 2016, 2013; Milano et al., 2010). 552 Cancer dissemination, cancer therapies and virus-induced lymphopenia might cause an 553 immunodeficiency that eventually jeopardizes virus clearance. The proposed mechanisms by 554 which lymphopenia occurs in COVID-19 (often shared with cancer dissemination) (Péron et 555 al., 2013) include virus-induced atrophy of secondary lymphoid organs (Buja et al., 2020; Lax 556 et al., 2020; Xu et al., 2020), disappearance of germinal centers (Kaneko et al., 2020), direct 557 pro-apoptotic activity of the virus related to ACE2-dependent or ACE2-independent entry 558 into lymphocytes (Pontelli et al., 2020), T cell demise consecutive to activation and 559 exhaustion (Channappanavar and Perlman, 2017; Park, 2020), senescence (Derosa et al., 560 2020; Westmeier et al., 2020), and antiproliferative effects of lactic acid (Fischer et al., 2007). 561 However, in our study, we found that lymphocyte loss was correlated with decrease of 562 secondary biliary salts in LVS patients, most likely associated with increased gut permeability 563 that lead to bacterial translocation, as we observed increased circulating DNA for 564 Micrococcaceae and Enterobacteriaceae family members. Moreover, the transformation of 565 spermidine into N1, N8 diacetylspermidine was linked to decreased ALC, in accordance with the role of spermidine in preventing ageing-related loss of lymphocyte fitness (Alsaleh et al., 566 567 2020; Puleston et al., 2014; Zhang et al., 2019).

568

Second, prolonged viral RNA carriage was associated with signs of immunopathology
(exacerbated T cell responses, extrafollicular TFH, and plasmablast recirculation, exhausted
PD-1⁺ Tc1 cells, sustained serum type 1 IFN levels), likely maintaining a positive feed-back
loop for the expression of the interferon-signaling genes product ACE2 (Ziegler et al., 2020)
and pro-inflammatory interactions between airway epithelia and immune cells (Chua et al.,
2020).

576 Third, prolonged SARS-CoV-2 RNA shedding after day 40 might precede the 577 aggravation of both COVID-19 and malignant disease. Indeed, virus and/or cancer-induced 578 lymphopenia and T cell exhaustion may jointly enfeeble tumor immunosurveillance (Rd et al., 579 2011). Interestingly, SARS-CoV-2 virus -induced immunopathology was accompanied by 580 increased blood levels of IL-8 (Figure S4G) and VEGF (Takahashi et al., 2020), which are 581 well known pro-angiogenic and pro-tumorigenic growth factors, predicting failure to cancer 582 immunotherapy (Sanmamed et al., 2017). Of note, patients with high initial viral loads or 583 LVS tended to accumulate poor prognosis-related parameters than SVS or patients with 584 higher Ct values in both cohorts (Table 1 & Table S1), being older (66 versus 56 years old, 585 p=0.08), more metastatic at diagnosis of infection (72% versus 29%, p=0.011), and increased 586 hospitalization rates (83% versus 23%, p=0.001). As a result, virus-induced lymphopenia 587 markedly predicted early death of patients, within the first 2-3 months post-COVID-19 588 diagnosis in the first and second surge of the pandemic (in more than 200 patients) and call 589 for caution to administer chemotherapy or steroids at the acute phase of the viral infection that 590 exacerbate immunosuppression.

591

592 These observations call for a careful follow up of cancer patients, in particular those 593 bearing hematological and metastatic malignancies, during the second wave of COVID-19. 594 Given the non-consensual efficacy of vaccines against influenza virus in vulnerable 595 individuals suffering from cancer-, virus- and age-associated lymphopenia (Bitterman et al., 596 2018; Péron et al., 2013), passive immunization of high affinity neutralizing monoclonal 597 antibodies against SARS-CoV-2 at COVID-19 onset might be envisaged. This could be 598 combined with therapeutic stimulation of lymphopoiesis (for instance with rIL-7, G-CSF, 599 inhibitors of indole amine 2,3 deoxygenase), to achieve an immunological tonus that is 600 compatible with anticancer treatments (Cheng et al., 2020; Francois et al., 2018; Laterre et al., 601 2020). Clinical trials are underway to evaluate rIL-7 against COVID-19, but may benefit from 602 patients stratification based on Ct values, duration of viral RNA shedding and ALC 603 (NCT04407689; NCT04426201; NCT04379076).

605 Acknowledgments: We are thankful to the Spectral flow cytometry facility team of Gustave Roussy. We thank

the ET-EXTRA team (Biological Resource Center (NF 96-600) and the microbiology team for technical help.

607 We thank Dr Aude Jary for helping to set up the subgenomic RNA analysis. We thank the staff from health and

safety of Gustave Roussy Cancer Campus for helping to set up the translational research studies. We are thankful

to the Genalyte for their supportive help.

610 Contributions: L.D., L.Z., A.M. and F.B. conceived and designed the clinical trial. A-G.G., L.D. and L.Z. 611 conceived and designed the translational research trial. A.G., F-X.D., S.T., C.M., L.A., B.B., A.St., B.G., 612 M.Mer., F.S., A.M., L.D. included patients in the clinical trial. A-G.G., A.D., F-X.D., M.Pic., M.Maz., A.S., 613 G.D. carried out all the experiments. A-G.G., A.D., F-X.D., A.S., and G.D. performed all the biological analysis. 614 D.D. performed the non-supervised analysis and gave advices for statistical analyses. L.D. and C.A-C-S. 615 collected and analyzed the clinical data. L.T. and A.F. provided the information from the HCW series. A.E., S.K. 616 and B.R. analyzed and provided the clinical data from the Canadian series. B. L.S., D.R., S.G. and S.C. analyzed 617 and provided the clinical data from the IHU series. G.G. and C.B. analyzed CT scan. E.C. and F.G. performed 618 the RT-qPCR. A-G.G., C. A-C-S. and M.Maz. collected the biological data (ALC and Ct values). C.P. collected 619 the samples. M.Maz., Y.H., E.P., C.F., G.F., C.T., I.L. and J-E. F. prepared the biological samples and provided 620 some help for the experiments. A-G.G., A.D. L.Z, and L.D. interpreted data. performed the viral cultures. M.My. 621 and G.G. performed the dosages of antibodies. F-X.D., C.G-D., S.D., N.N., F.A. and A-G.G performed the 622 metagenomic experiments and analyses. B.L., A.R. and A.D. performed metagenomic analyses of blood 623 microbiota. All the authors advised for the interpretation of the data. O.K. gave advices for the design of the 624 figures. L.Z. and L.D. wrote the manuscript, with all authors contributing to writing and providing feedback.

625 Funding: A-G.G. was supported by Fondation pour la Recherche Médicale (FRM). L.D. has received support by 626 the Philanthropia Fondation Gustave Roussy. The Gustave Roussy sponsored clinical study on COVID-19 627 (ONCOVID; NCT NCT04341207 has been supported by the Fondation Gustave Roussy, the Dassault family, 628 Malakoff Humanis, Agnès b., Izipizi, Ralph Lauren and Sanofi). L.Z. and G.K. were supported by RHU Torino 629 Lumière (ANR-16-RHUS-0008), ONCOBIOME H2020 network, the Seerave Foundation, the Ligue contre le 630 Cancer (équipe labelisée); Agence Nationale de la Recherche (ANR) - Projets blancs; ANR under the frame of 631 E-Rare-2, the ERA-Net for Research on Rare Diseases; Association pour la recherche sur le cancer (ARC); 632 Cancéropôle Ile-de-France; FRM; a donation by Elior; the European Research Council (ERC); Fondation 633 Carrefour; High-end Foreign Expert Program in China (GDW20171100085 and GDW20181100051), Institut 634 National du Cancer (INCa); Inserm (HTE); Institut Universitaire de France; LeDucq Foundation; the LabEx 635 Immuno-Oncology; the SIRIC Stratified Oncology Cell DNA Repair and Tumor Immune Elimination 636 (SOCRATE); CARE network (directed by Prof. Mariette, Kremlin Bicêtre AP-HP), and the SIRIC Cancer 637 Research and Personalized Medicine (CARPEM). G.I. and M.P. were supported by Italian Ministry of Health 638 (grants Ricerca CorrenteLinea 1, 1 'Infezioni Emergenti e Riemergenti', projects COVID-2020-12371675 and 639 COVID 2020 12371817). M.My and G.G. were supported by ANR Flash COVID19 program and ARS-CoV-640 2 Program of the Faculty of Medicine from Sorbonne University ICOViD programs (PI: G.G.).

641 The authors declare the following competing interests: L.Z. and G.K. are cofounders of everImmune, a 642 biotech company devoted to the use of commensal microbes for the treatment of cancers. A.G. and A.M. as part 643 of the Drug Development Department (DITEP) are Principal/sub-Investigator of Clinical Trials for Abbvie,

644 Adaptimmune, Aduro Biotech, Agios Pharmaceuticals, Amgen, Argen-X Bvba, Arno Therapeutics, Astex 645 Pharmaceuticals, Astra Zeneca, Astra Zeneca Ab, Aveo, Bayer Healthcare Ag, Bbb Technologies Bv, Beigene, 646 Bioalliance Pharma, Biontech Ag, Blueprint Medicines, Boehringer Ingelheim, Boston Pharmaceuticals, Bristol 647 Myers Squibb, Bristol-Myers Squibb International Corporation, Ca, Celgene Corporation, Cephalon, Chugai 648 Pharmaceutical Co., Clovis Oncology, Cullinan-Apollo, Daiichi Sankyo, Debiopharm S.A., Eisai, Eisai Limited, 649 Eli Lilly, Exelixis, Forma Tharapeutics, Gamamabs, Genentech, Gilead Sciences, Glaxosmithkline, Glenmark 650 Pharmaceuticals, H3 Biomedicine, Hoffmann La Roche Ag, Incyte Corporation, Innate Pharma, Institut De 651 Recherche Pierre Fabre, Iris Servier, Janssen Cilag, Janssen Research Foundation, Kura Oncology, Kyowa Kirin 652 Pharm. Dev., Lilly France, Loxo Oncology, Lytix Biopharma As, Medimmune, Menarini Ricerche, Merck Kgaa, 653 Merck Sharp & Dohme Chibret, Merrimack Pharmaceuticals, Merus, Millennium Pharmaceuticals, Molecular 654 Partners Ag, Nanobiotix, Nektar Therapeutics, Nerviano Medical Sciences, Novartis Pharma, Octimet Oncology 655 Nv, Oncoethix, Oncomed, Oncopeptides, Onyx Therapeutics, Orion Pharma, Oryzon Genomics, Ose Pharma, 656 Pfizer, Pharma Mar, Philogen S.P.A., Pierre Fabre Medicament, Plexxikon, Rigontec Gmbh, Roche, Sanofi 657 Aventis, Sierra Oncology, Sotio A.S, Syros Pharmaceuticals, Taiho Pharma, Tesaro, Tioma Therapeutics, Wyeth 658 Pharmaceuticals France, Xencor, Y's Therapeutics, Research Grants from Astrazeneca, BMS, Boehringer 659 Ingelheim, Janssen Cilag, Merck, Novartis, Pfizer, Roche, Sanofi. Non-financial support (drug supplied) from 660 Astrazeneca, Bayer, BMS, Boringher Ingelheim, Johnson & Johnson, Lilly, Medimmune, Merck, NH 661 TherAGuiX, Pfizer, Roche. N.L. reports to be a Speaker at Jazz Pharmaceutical E.D. reports grants and personal 662 fees from ROCHE GENENTECH, grants from SERVIER, grants from ASTRAZENECA, grants and personal 663 fees from MERCK SERONO, grants from BMS, grants from MSD, outside the submitted work. O.K. is a 664 cofounder of Samsara Therapeutics. F.B. reports personal fees from Astra-Zeneca, Bayer, Bristol-Myers Squibb, 665 Boehringer-Ingelheim, Eli Lilly Oncology, B. Hoffmann-La Roche Ltd, Novartis, Merck, MSD, Pierre Fabre, 666 Pfizer and Takeda, outside the submitted work. J-C. S. was a full time employee of AstraZeneca between 667 September 2017 and December 2019, he reports consultancy: Relay Therapeutics, Gritstone Oncology and 668 shares: Gritstone, AstraZeneca, Daiichi-Sankyo, outside the submitted work. L.A. reports consulting fees 669 compensated to institution for Pfizer, Novartis, Bristol Myer Squibb, Ipsen, Roche, MSD, Astra Zeneca, Merck, 670 Amgen, Astellas, Exelixis, Corvus Pharmaceuticals, Peloton Therapeutics, outside the submitted work. F.S. 671 reports consulting fees from AMGEN, Roche, Chugai, Mylan, Mundi Pharma, Leo Pharma, Pierre Fabre 672 Oncology, Helsinn, MSD, Pfizer, BMS, outside the submitted work.

Data and materials availability: This study includes no data deposited in external repositories.

675 **References**

676	Albiges, L., Foulon, S., Bayle, A., Gachot, B., Pommeret, F., Willekens, C., Stoclin, A.,					
677	Merad, M., Griscelli, F., Lacroix, L., Netzer, F., Hueso, T., Balleyguier, C., Ammari,					
678	S., Colomba, E., Baciarello, G., Perret, A., Hollebecque, A., Hadoux, J., Michot, J					
679	M., Chaput, N., Saada, V., Hauchecorne, M., Micol, JB., Sun, R., Valteau-Couanet,					
680	D., André, F., Scotte, F., Besse, B., Soria, JC., Barlesi, F., 2020. Determinants of the					
681	outcomes of patients with cancer infected with SARS-CoV-2: results from the					
682	Gustave Roussy cohort. Nature Cancer 1, 965–975. https://doi.org/10.1038/s43018-					
683	020-00120-5					
684	Alsaleh, G., Panse, I., Swadling, L., Zhang, H., Richter, F.C., Meyer, A., Lord, J., Barnes, E.,					
685	Klenerman, P., Green, C., Simon, A.K., 2020. Autophagy in T cells from aged donors					
686	is maintained by spermidine and correlates with function and vaccine responses. Elife					
687	9. https://doi.org/10.7554/eLife.57950					
688	Amrane, S., Tissot-Dupont, H., Doudier, B., Eldin, C., Hocquart, M., Mailhe, M., Dudouet,					
689	P., Ormières, E., Ailhaud, L., Parola, P., Lagier, JC., Brouqui, P., Zandotti, C.,					
690	Ninove, L., Luciani, L., Boschi, C., La Scola, B., Raoult, D., Million, M., Colson, P.,					
691	Gautret, P., 2020. Rapid viral diagnosis and ambulatory management of suspected					
692	COVID-19 cases presenting at the infectious diseases referral hospital in Marseille,					
693	France, - January 31st to March 1st, 2020: A respiratory virus snapshot. Travel Med					
694	Infect Dis 36, 101632. https://doi.org/10.1016/j.tmaid.2020.101632					
695	Anhê, F.F., Jensen, B.A.H., Varin, T.V., Servant, F., Van Blerk, S., Richard, D., Marceau, S.,					
696	Surette, M., Biertho, L., Lelouvier, B., Schertzer, J.D., Tchernof, A., Marette, A.,					
697	2020. Type 2 diabetes influences bacterial tissue compartmentalisation in human					
698	obesity. Nature Metabolism 2, 233–242. https://doi.org/10.1038/s42255-020-0178-9					
699	Arunachalam, P.S., Wimmers, F., Mok, C.K.P., Perera, R.A.P.M., Scott, M., Hagan, T., Sigal,					
700	N., Feng, Y., Bristow, L., Tsang, O.TY., Wagh, D., Coller, J., Pellegrini, K.L.,					
701	Kazmin, D., Alaaeddine, G., Leung, W.S., Chan, J.M.C., Chik, T.S.H., Choi, C.Y.C.,					
702	Huerta, C., McCullough, M.P., Lv, H., Anderson, E., Edupuganti, S., Upadhyay, A.A.,					
703	Bosinger, S.E., Maecker, H.T., Khatri, P., Rouphael, N., Peiris, M., Pulendran, B.,					
704	2020. Systems biological assessment of immunity to mild versus severe COVID-19					
705	infection in humans. Science 369, 1210–1220.					
706	https://doi.org/10.1126/science.abc6261					
707	Assaad, S., Avrillon, V., Fournier, ML., Mastroianni, B., Russias, B., Swalduz, A., Cassier,					
708	P., Eberst, L., Steineur, MP., Kazes, M., Perol, M., Michallet, AS., Rey, P., Erena-					
709	Penet, AS., Morel, A., Brahmi, M., Dufresne, A., Tredan, O., Chvetzoff, G., Fayette,					
710	J., de la Fouchardiere, C., Ray-Coquard, I., Bachelot, T., Saintigny, P., Tabutin, M.,					
711	Dupré, A., Nicolas-Virelizier, E., Belhabri, A., Roux, PE., Fuhrmann, C., Pilleul, F.,					
712	Basle, A., Bouhamama, A., Galvez, C., Herr, AL., Gautier, J., Chabaud, S., Zrounba,					
713	P., Perol, D., Blay, JY., 2020. High mortality rate in cancer patients with symptoms					
714	of COVID-19 with or without detectable SARS-COV-2 on RT-PCR. European					
715	Journal of Cancer 135, 251–259. https://doi.org/10.1016/j.ejca.2020.05.028					
716	Avanzato, V.A., Matson, M.J., Seifert, S.N., Pryce, R., Williamson, B.N., Anzick, S.L.,					
717	Barbian, K., Judson, S.D., Fischer, E.R., Martens, C., Bowden, T.A., de Wit, E.,					
718	Riedo, F.X., Munster, V.J., 2020. Case Study: Prolonged Infectious SARS-CoV-2					
719	Shedding from an Asymptomatic Immunocompromised Individual with Cancer. Cell					
720	183, 1901-1912.e9. https://doi.org/10.1016/j.cell.2020.10.049					
721	Aydillo, T., Gonzalez-Reiche, A.S., Aslam, S., van de Guchte, A., Khan, Z., Obla, A., Dutta,					
722	J., van Bakel, H., Aberg, J., García-Sastre, A., Shah, G., Hohl, T., Papanicolaou, G.,					
723	Perales, MA., Sepkowitz, K., Babady, N.E., Kamboj, M., 2020. Shedding of Viable					

724	SARS-CoV-2 after Immunosuppressive Therapy for Cancer. N Engl J Med 383,					
725	2586-2588. https://doi.org/10.1056/NEJMc2031670					
726	Becht, E., McInnes, L., Healy, J., Dutertre, CA., Kwok, I.W.H., Ng, L.G., Ginhoux, F.,					
727	Newell, E.W., 2019. Dimensionality reduction for visualizing single-cell data using					
728	UMAP. Nature Biotechnology 37, 38–44. https://doi.org/10.1038/nbt.4314					
729	Bitterman, R., Eliakim Raz, N., Vinograd, I., Trestioreanu, A.Z., Leibovici, L., Paul, M.,					
730	2018. Influenza vaccines in immunosuppressed adults with cancer. Cochrane Database					
731	of Systematic Reviews. https://doi.org/10.1002/14651858.CD008983.pub3					
732	Boutin, CA., Grandjean-Lapierre, S., Gagnon, S., Labbé, AC., Charest, H., Roger, M.,					
733	Coutlée, F., 2020. Comparison of SARS-CoV-2 detection from combined					
734	nasopharyngeal/oropharyngeal swab samples by a laboratory-developed real-time RT-					
735	PCR test and the Roche SARS-CoV-2 assay on a cobas 8800 instrument. J Clin Virol					
736	132, 104615. https://doi.org/10.1016/j.jcv.2020.104615					
737	Buja, L.M., Wolf, D.A., Zhao, B., Akkanti, B., McDonald, M., Lelenwa, L., Reilly, N.,					
738	Ottaviani, G., Elghetany, M.T., Trujillo, D.O., Aisenberg, G.M., Madjid, M., Kar, B.,					
739	2020. The emerging spectrum of cardiopulmonary pathology of the coronavirus					
740	disease 2019 (COVID-19): Report of 3 autopsies from Houston, Texas, and review of					
741	autopsy findings from other United States cities. Cardiovasc Pathol 48, 107233.					
742	https://doi.org/10.1016/j.carpath.2020.107233					
743	Campbell, C., McKenney, P.T., Konstantinovsky, D., Isaeva, O.I., Schizas, M., Verter, J.,					
744	Mai, C., Jin, WB., Guo, CJ., Violante, S., Ramos, R.J., Cross, J.R., Kadaveru, K.,					
745	Hambor, J., Rudensky, A.Y., 2020. Bacterial metabolism of bile acids promotes					
746	generation of peripheral regulatory T cells. Nature 581, 475–479.					
747	https://doi.org/10.1038/s41586-020-2193-0					
748	Carvelli, J., Demaria, O., Vély, F., Batista, L., Benmansour, N.C., Fares, J., Carpentier, S.,					
749	Thibult, ML., Morel, A., Remark, R., André, P., Represa, A., Piperoglou, C.,					
750	Cordier, P.Y., Dault, E.L., Guervilly, C., Simeone, P., Gainnier, M., Morel, Y., Ebbo,					
751	M., Schleinitz, N., Vivier, E., 2020. Association of COVID-19 inflammation with					
752	activation of the C5a-C5aR1 axis. Nature 1-5. https://doi.org/10.1038/s41586-020-					
753	2600-6					
754	Channappanavar, R., Perlman, S., 2017. Pathogenic human coronavirus infections: causes and					
755	consequences of cytokine storm and immunopathology. Semin Immunopathol 39,					
756	529–539. https://doi.org/10.1007/s00281-017-0629-x					
757	Cheng, LL., Guan, WJ., Duan, CY., Zhang, NF., Lei, CL., Hu, Y., Chen, AL., Li, S					
758	Y., Zhuo, C., Deng, XL., Cheng, FJ., Gao, Y., Zhang, JH., Xie, JX., Peng, Hong,					
759	Li, YX., Wu, XX., Liu, W., Peng, Hui, Wang, J., Xiao, GM., Chen, PY., Wang,					
760	CY., Yang, ZF., Zhao, JC., Zhong, NS., 2020. Effect of Recombinant Human					
761	Granulocyte Colony-Stimulating Factor for Patients With Coronavirus Disease 2019					
762	(COVID-19) and Lymphopenia: A Randomized Clinical Trial. JAMA Intern Med.					
763	https://doi.org/10.1001/jamainternmed.2020.5503					
764	Choi, B., Choudhary, M.C., Regan, J., Sparks, J.A., Padera, R.F., Qiu, X., Solomon, I.H.,					
765	Kuo, HH., Boucau, J., Bowman, K., Adhikari, U.D., Winkler, M.L., Mueller, A.A.,					
766	Hsu, T.YT., Desjardins, M., Baden, L.R., Chan, B.T., Walker, B.D., Lichterfeld, M.,					
767	Brigl, M., Kwon, D.S., Kanjilal, S., Richardson, E.T., Jonsson, A.H., Alter, G.,					
768	Barczak, A.K., Hanage, W.P., Yu, X.G., Gaiha, G.D., Seaman, M.S., Cernadas, M.,					
769	Li, J.Z., 2020. Persistence and Evolution of SARS-CoV-2 in an Immunocompromised					
770	Host. N Engl J Med. https://doi.org/10.1056/NEJMc2031364					
771	Chua, R.L., Lukassen, S., Trump, S., Hennig, B.P., Wendisch, D., Pott, F., Debnath, O., Thürmann, L., Kurth, E., Välkar, M.T., Kazmiarski, L., Timmarmann, B., Twardrick					
772	Thürmann, L., Kurth, F., Völker, M.T., Kazmierski, J., Timmermann, B., Twardziok,					
773	S., Schneider, S., Machleidt, F., Müller-Redetzky, H., Maier, M., Krannich, A.,					

774	Schmidt, S., Balzer, F., Liebig, J., Loske, J., Suttorp, N., Eils, J., Ishaque, N., Liebert,					
775	U.G., von Kalle, C., Hocke, A., Witzenrath, M., Goffinet, C., Drosten, C., Laudi, S.,					
776	Lehmann, I., Conrad, C., Sander, LE., Eils, R., 2020. COVID-19 severity correlates					
777	· · · · · · · · · · · ·					
	with airway epithelium–immune cell interactions identified by single-cell analysis.					
778	Nature Biotechnology 38, 970–979. https://doi.org/10.1038/s41587-020-0602-4					
779	Corman, V.M., Landt, O., Kaiser, M., Molenkamp, R., Meijer, A., Chu, D.K., Bleicker, T.,					
780	Brünink, S., Schneider, J., Schmidt, M.L., Mulders, D.G., Haagmans, B.L., van der					
781	Veer, B., van den Brink, S., Wijsman, L., Goderski, G., Romette, JL., Ellis, J.,					
782	Zambon, M., Peiris, M., Goossens, H., Reusken, C., Koopmans, M.P., Drosten, C.,					
783	2020. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Euro					
784	Surveill 25. https://doi.org/10.2807/1560-7917.ES.2020.25.3.2000045					
785	Dai, M., Liu, D., Liu, M., Zhou, F., Li, G., Chen, Z., Zhang, Z., You, H., Wu, M., Zheng, Q.,					
786	Xiong, Y., Xiong, H., Wang, C., Chen, C., Xiong, F., Zhang, Y., Peng, Y., Ge, S.,					
787	Zhen, B., Yu, T., Wang, L., Wang, H., Liu, Y., Chen, Y., Mei, J., Gao, X., Li, Zhuyan,					
788	Gan, L., He, C., Li, Zhen, Shi, Y., Qi, Y., Yang, J., Tenen, D.G., Chai, L., Mucci,					
789	L.A., Santillana, M., Cai, H., 2020. Patients with Cancer Appear More Vulnerable to					
790	SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak. Cancer Discov					
791	10, 783–791. https://doi.org/10.1158/2159-8290.CD-20-0422					
792	Danlos, FX., Grajeda-Iglesias, C., Durand, S., Sauvat, A., Roumier, M., Cantin, D.,					
793	Colomba, E., Rohmer, J., Pommeret, F., Baciarello, G., et al., In Press. Metabolomic					
794	analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers.					
795	Cell Death & Disease.					
796	Derosa, L., Melenotte, C., Griscelli, F., Gachot, B., Marabelle, A., Kroemer, G., Zitvogel, L.,					
790 797						
	2020. The immuno-oncological challenge of COVID-19. Nature Cancer 1, 946–964.					
798 700	https://doi.org/10.1038/s43018-020-00122-3					
799	El Ramahi, R., Freifeld, A., 2019. Epidemiology, Diagnosis, Treatment, and Prevention of					
800	Influenza Infection in Oncology Patients. JOP 15, 177–184.					
801	https://doi.org/10.1200/JOP.18.00567					
802	Elkrief, A., Desilets, A., Papneja, N., Cvetkovic, L., Groleau, C., Lakehal, Y.A., Shbat, L.,					
803	Richard, C., Malo, J., Belkaid, W., Cook, E., Doucet, S., Tran, T.H., Jao, K., Daaboul,					
804	N., Bhang, E., Loree, J.M., Miller, W.H., Vinh, D.C., Bouganim, N., Batist, G.,					
805	Letendre, C., Routy, B., 2020. High mortality among hospital-acquired COVID-19					
806	infection in patients with cancer: A multicentre observational cohort study. European					
807	Journal of Cancer 139, 181–187. https://doi.org/10.1016/j.ejca.2020.08.017					
808	Escudié, F., Auer, L., Bernard, M., Mariadassou, M., Cauquil, L., Vidal, K., Maman, S.,					
809	Hernandez-Raquet, G., Combes, S., Pascal, G., 2018. FROGS: Find, Rapidly, OTUs					
810	with Galaxy Solution. Bioinformatics 34, 1287–1294.					
811	https://doi.org/10.1093/bioinformatics/btx791					
812	Fischer, K., Hoffmann, P., Voelkl, S., Meidenbauer, N., Ammer, J., Edinger, M., Gottfried,					
813	E., Schwarz, S., Rothe, G., Hoves, S., Renner, K., Timischl, B., Mackensen, A., Kunz-					
814	Schughart, L., Andreesen, R., Krause, S.W., Kreutz, M., 2007. Inhibitory effect of					
815	tumor cell-derived lactic acid on human T cells. Blood 109, 3812–3819.					
816	https://doi.org/10.1182/blood-2006-07-035972					
017	· · ·					
817	Francois, B., Jeannet, R., Daix, T., Walton, A.H., Shotwell, M.S., Unsinger, J., Monneret, G.,					
	Francois, B., Jeannet, R., Daix, T., Walton, A.H., Shotwell, M.S., Unsinger, J., Monneret, G., Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K.,					
818	Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K.,					
818 819	Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K., Sherwood, E.R., Hotchkiss, R.S., 2018. Interleukin-7 restores lymphocytes in septic					
818 819 820	Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K., Sherwood, E.R., Hotchkiss, R.S., 2018. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3.					
818 819 820 821	Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K., Sherwood, E.R., Hotchkiss, R.S., 2018. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3. https://doi.org/10.1172/jci.insight.98960					
818 819 820	Rimmelé, T., Blood, T., Morre, M., Gregoire, A., Mayo, G.A., Blood, J., Durum, S.K., Sherwood, E.R., Hotchkiss, R.S., 2018. Interleukin-7 restores lymphocytes in septic shock: the IRIS-7 randomized clinical trial. JCI Insight 3.					

824	A., Chini, C., Cortellini, A., Felip, E., Finocchiaro, G., Garrido, P., Genova, C., Giusti,						
825	R., Gregorc, V., Grossi, F., Grosso, F., Intagliata, S., La Verde, N., Liu, S.V.,						
826	Mazieres, J., Mercadante, E., Michielin, O., Minuti, G., Moro-Sibilot, D., Pasello, G.,						
827	Passaro, A., Scotti, V., Solli, P., Stroppa, E., Tiseo, M., Viscardi, G., Voltolini, L.,						
828	Wu, YL., Zai, S., Pancaldi, V., Dingemans, AM., Van Meerbeeck, J., Barlesi, F.,						
829	Wakelee, H., Peters, S., Horn, L., TERAVOLT investigators, 2020. COVID-19 in						
830	patients with thoracic malignancies (TERAVOLT): first results of an international,						
831	registry-based, cohort study. Lancet Oncol 21, 914–922.						
832	https://doi.org/10.1016/S1470-2045(20)30314-4						
833	Ge, H., Wang, X., Yuan, X., Xiao, G., Wang, C., Deng, T., Yuan, Q., Xiao, X., 2020. The						
834	epidemiology and clinical information about COVID-19. Eur J Clin Microbiol Infect						
835	Dis 1–9. https://doi.org/10.1007/s10096-020-03874-z						
836	Geis, S., Prifert, C., Weissbrich, B., Lehners, N., Egerer, G., Eisenbach, C., Buchholz, U.,						
837	Aichinger, E., Dreger, P., Neben, K., Burkhardt, U., Ho, A.D., Kräusslich, HG.,						
838	Heeg, K., Schnitzler, P., 2013. Molecular characterization of a respiratory syncytial						
839	virus outbreak in a hematology unit in Heidelberg, Germany. J Clin Microbiol 51,						
840	155–162. https://doi.org/10.1128/JCM.02151-12						
841	Helleberg, M., Niemann, C.U., Moestrup, K.S., Kirk, O., Lebech, AM., Lane, C., Lundgren,						
842	J., 2020. Persistent COVID-19 in an Immunocompromised Patient Temporarily						
843	Responsive to Two Courses of Remdesivir Therapy. J Infect Dis 222, 1103–1107.						
844	https://doi.org/10.1093/infdis/jiaa446						
845	Jaafar, R., Aherfi, S., Wurtz, N., Grimaldier, C., Hoang, V.T., Colson, P., Raoult, D., La						
846	Scola, B., 2020. Correlation between 3790 qPCR positives samples and positive cell						
847	cultures including 1941 SARS-CoV-2 isolates. Clin Infect Dis.						
848	https://doi.org/10.1093/cid/ciaa1491						
849	Kampen, J.J.A. van, Vijver, D.A.M.C. van de, Fraaij, P.L.A., Haagmans, B.L., Lamers, M.M.,						
850	Okba, N., Akker, J.P.C. van den, Endeman, H., Gommers, D.A.M.P.J., Cornelissen,						
851	J.J., Hoek, R.A.S., Eerden, M.M. van der, Hesselink, D.A., Metselaar, H.J., Verbon,						
852	A., Steenwinkel, J.E.M. de, Aron, G.I., Gorp, E.C.M. van, Boheemen, S. van,						
853	Voermans, J.C., Boucher, C.A.B., Molenkamp, R., Koopmans, M.P.G.,						
854	Geurtsvankessel, C., Eijk, A.A. van der, 2020. Shedding of infectious virus in						
855	hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key						
856	determinants. medRxiv 2020.06.08.20125310.						
857	https://doi.org/10.1101/2020.06.08.20125310						
858	Kaneko, N., Kuo, HH., Boucau, J., Farmer, J.R., Allard-Chamard, H., Mahajan, V.S.,						
859	Piechocka-Trocha, A., Lefteri, K., Osborn, M., Bals, J., Bartsch, Y.C., Bonheur, N.,						
860	Caradonna, T.M., Chevalier, J., Chowdhury, F., Diefenbach, T.J., Einkauf, K., Fallon,						
861	J., Feldman, J., Finn, K.K., Garcia-Broncano, P., Hartana, C.A., Hauser, B.M., Jiang,						
862	C., Kaplonek, P., Karpell, M., Koscher, E.C., Lian, X., Liu, H., Liu, J., Ly, N.L.,						
863	Michell, A.R., Rassadkina, Y., Seiger, K., Sessa, L., Shin, S., Singh, N., Sun, W., Sun,						
864	X., Ticheli, H.J., Waring, M.T., Zhu, A.L., Alter, G., Li, J.Z., Lingwood, D., Schmidt,						
865	A.G., Lichterfeld, M., Walker, B.D., Yu, X.G., Padera, R.F., Pillai, S., 2020. Loss of						
865	Bcl-6-Expressing T Follicular Helper Cells and Germinal Centers in COVID-19. Cell						
867	183, 143-157.e13. https://doi.org/10.1016/j.cell.2020.08.025						
868	Lagier, JC., Million, M., Gautret, P., Colson, P., Cortaredona, S., Giraud-Gatineau, A.,						
868 869	Honoré, S., Gaubert, JY., Fournier, PE., Tissot-Dupont, H., Chabrière, E., Stein, A.,						
809 870	Deharo, JC., Fenollar, F., Rolain, JM., Obadia, Y., Jacquier, A., La Scola, B.,						
870 871	Brouqui, P., Drancourt, M., Parola, P., Raoult, D., 2020. Outcomes of 3,737 COVID-						
871	19 patients treated with hydroxychloroquine/azithromycin and other regimens in						
014	17 patients treated with hydroxyemoroquine/aziunomyem and outer regimens m						

873	Marseille, France: A retrospective analysis. Travel Med Infect Dis 36, 101791.
874	https://doi.org/10.1016/j.tmaid.2020.101791
875	Laing, A.G., Lorenc, A., del Molino del Barrio, I., Das, A., Fish, M., Monin, L., Muñoz-Ruiz,
876	M., McKenzie, D.R., Hayday, T.S., Francos-Quijorna, I., Kamdar, S., Joseph, M.,
877	Davies, D., Davis, R., Jennings, A., Zlatareva, I., Vantourout, P., Wu, Y., Sofra, V.,
878	Cano, F., Greco, M., Theodoridis, E., Freedman, J., Gee, S., Chan, J.N.E., Ryan, S.,
879	Bugallo-Blanco, E., Peterson, P., Kisand, K., Haljasmägi, L., Chadli, L., Moingeon,
880	P., Martinez, L., Merrick, B., Bisnauthsing, K., Brooks, K., Ibrahim, M.A.A., Mason,
881	J., Lopez Gomez, F., Babalola, K., Abdul-Jawad, S., Cason, J., Mant, C., Seow, J.,
882	Graham, C., Doores, K.J., Di Rosa, F., Edgeworth, J., Shankar-Hari, M., Hayday,
883	A.C., 2020. A dynamic COVID-19 immune signature includes associations with poor
884	prognosis. Nature Medicine 26, 1623–1635. https://doi.org/10.1038/s41591-020-1038-
885	6
886	Laterre, P.F., François, B., Collienne, C., Hantson, P., Jeannet, R., Remy, K.E., Hotchkiss,
887	R.S., 2020. Association of Interleukin 7 Immunotherapy With Lymphocyte Counts
888	Among Patients With Severe Coronavirus Disease 2019 (COVID-19). JAMA Netw
889	Open 3. https://doi.org/10.1001/jamanetworkopen.2020.16485
890	Lax, S.F., Skok, K., Zechner, P., Kessler, H.H., Kaufmann, N., Koelblinger, C., Vander, K.,
891	Bargfrieder, U., Trauner, M., 2020. Pulmonary Arterial Thrombosis in COVID-19
892	With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic
893	Case Series. Ann Intern Med 173, 350–361. https://doi.org/10.7326/M20-2566
894	Lehners, N., Schnitzler, P., Geis, S., Puthenparambil, J., Benz, M.A., Alber, B., Luft, T.,
895	Dreger, P., Eisenbach, C., Kunz, C., Benner, A., Buchholz, U., Aichinger, E., Frank,
896	U., Heeg, K., Ho, A.D., Egerer, G., 2013. Risk factors and containment of respiratory
897	syncytial virus outbreak in a hematology and transplant unit. Bone Marrow
898	Transplantation 48, 1548–1553. https://doi.org/10.1038/bmt.2013.94
899	Lehners, N., Tabatabai, J., Prifert, C., Wedde, M., Puthenparambil, J., Weissbrich, B., Biere,
900	B., Schweiger, B., Egerer, G., Schnitzler, P., 2016. Long-Term Shedding of Influenza
901 902	Virus, Parainfluenza Virus, Respiratory Syncytial Virus and Nosocomial
902 903	Epidemiology in Patients with Hematological Disorders. PLOS ONE 11, e0148258. https://doi.org/10.1371/journal.pone.0148258
903 904	Li, Q., Guan, X., Wu, P., Wang, X., Zhou, L., Tong, Y., Ren, R., Leung, K.S.M., Lau, E.H.Y.,
904 905	Wong, J.Y., Xing, X., Xiang, N., Wu, Y., Li, C., Chen, Q., Li, D., Liu, T., Zhao, J.,
905 906	Liu, M., Tu, W., Chen, C., Jin, L., Yang, R., Wang, Q., Zhou, S., Wang, R., Liu, H.,
900 907	Luo, Y., Liu, Y., Shao, G., Li, H., Tao, Z., Yang, Y., Deng, Z., Liu, B., Ma, Z., Zhang,
908	Y., Shi, G., Lam, T.T.Y., Wu, J.T., Gao, G.F., Cowling, B.J., Yang, B., Leung, G.M.,
909	Feng, Z., 2020. Early Transmission Dynamics in Wuhan, China, of Novel
910	Coronavirus–Infected Pneumonia. New England Journal of Medicine 382, 1199–1207.
911	https://doi.org/10.1056/NEJMoa2001316
912	Lluch, J., Servant, F., Païssé, S., Valle, C., Valière, S., Kuchly, C., Vilchez, G., Donnadieu,
913	C., Courtney, M., Burcelin, R., Amar, J., Bouchez, O., Lelouvier, B., 2015. The
914	Characterization of Novel Tissue Microbiota Using an Optimized 16S Metagenomic
915	Sequencing Pipeline. PLOS ONE 10, e0142334.
916	https://doi.org/10.1371/journal.pone.0142334
917	Luo, J., Rizvi, H., Preeshagul, I.R., Egger, J.V., Hoyos, D., Bandlamudi, C., McCarthy, C.G.,
918	Falcon, C.J., Schoenfeld, A.J., Arbour, K.C., Chaft, J.E., Daly, R.M., Drilon, A., Eng,
919	J., Iqbal, A., Lai, W.V., Li, B.T., Lito, P., Namakydoust, A., Ng, K., Offin, M., Paik,
920	P.K., Riely, G.J., Rudin, C.M., Yu, H.A., Zauderer, M.G., Donoghue, M.T.A., Łuksza,
921	M Greenhaum B D Kris M G Hellmann M D 2020 COVID-19 in patients with

M., Greenbaum, B.D., Kris, M.G., Hellmann, M.D., 2020. COVID-19 in patients with 921

922	lung cancer. Annals of Oncology 31, 1386–1396.					
923	https://doi.org/10.1016/j.annonc.2020.06.007					
924	Martín Moro, F., Marquet, J., Piris, M., Michael, B.M., Sáez, A.J., Corona, M., Jiménez, C.,					
925	Astibia, B., García, I., Rodríguez, E., García Hoz, C., Fortún Abete, J., Herrera, P.,					
926	López Jiménez, J., 2020. Survival study of hospitalised patients with concurrent					
927	COVID-19 and haematological malignancies. British Journal of Haematology 190,					
928	e16-e20. https://doi.org/10.1111/bjh.16801					
929	Mathew, D., Giles, J.R., Baxter, A.E., Oldridge, D.A., Greenplate, A.R., Wu, J.E., Alanio, C.,					
930	Kuri-Cervantes, L., Pampena, M.B., D'Andrea, K., Manne, S., Chen, Z., Huang, Y.J.,					
931	Reilly, J.P., Weisman, A.R., Ittner, C.A.G., Kuthuru, O., Dougherty, J., Nzingha, K.,					
932	Han, N., Kim, J., Pattekar, A., Goodwin, E.C., Anderson, E.M., Weirick, M.E.,					
933	Gouma, S., Arevalo, C.P., Bolton, M.J., Chen, F., Lacey, S.F., Ramage, H., Cherry, S.,					
934	Hensley, S.E., Apostolidis, S.A., Huang, A.C., Vella, L.A., Unit [†] , T.Up.C.P., Betts,					
935	M.R., Meyer, N.J., Wherry, E.J., 2020. Deep immune profiling of COVID-19 patients					
936	reveals distinct immunotypes with therapeutic implications. Science 369.					
937	https://doi.org/10.1126/science.abc8511					
938	Milano, F., Campbell, A.P., Guthrie, K.A., Kuypers, J., Englund, J.A., Corey, L., Boeckh, M.,					
939	2010. Human rhinovirus and coronavirus detection among allogeneic hematopoietic					
940	stem cell transplantation recipients. Blood 115, 2088–2094.					
941	https://doi.org/10.1182/blood-2009-09-244152					
942	Moole, P.K.R., Papireddypalli, J.M.R., 2020. Effect of Deoxycholic Acid on Immune Cells -					
943	An Immunophenotyping Analysis of Peripheral Blood and Splenic Lymphocytes in					
944	CD57 Female Mice. International Journal of Pharmaceutical Investigation 10, 548–					
945	552. https://doi.org/10.5530/ijpi.2020.4.95					
946	NCT04407689, n.d. A Multicenter, Randomized, Double-blinded Placebo-controlled Study of					
947	Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized					
948	Lymphopenic Patients With Coronavirus COVID-19 Infection in France and Belgium					
949	(Clinical trial registration No. NCT04407689). clinicaltrials.gov.					
950	NCT04426201, n.d. A Multicenter, Randomized, Double-blinded Placebo-controlled Study of					
951	Recombinant Interleukin-7 (CYT107) for Immune Restoration of Hospitalized					
952	Lymphopenic Patients With Coronavirus COVID-19 Infection. US Oncology Cohort					
953	(Clinical trial registration No. NCT04426201). clinicaltrials.gov.					
954	Païssé, S., Valle, C., Servant, F., Courtney, M., Burcelin, R., Amar, J., Lelouvier, B., 2016.					
955	Comprehensive description of blood microbiome from healthy donors assessed by 16S					
956	targeted metagenomic sequencing. Transfusion 56, 1138–1147.					
957	https://doi.org/10.1111/trf.13477					
958	Park, M.D., 2020. Macrophages: a Trojan horse in COVID-19? Nature Reviews Immunology					
959	20, 351–351. https://doi.org/10.1038/s41577-020-0317-2					
960	Passamonti, F., Cattaneo, C., Arcaini, L., Bruna, R., Cavo, M., Merli, F., Angelucci, E.,					
961	Krampera, M., Cairoli, R., Della Porta, M.G., Fracchiolla, N., Ladetto, M.,					
962	Gambacorti Passerini, C., Salvini, M., Marchetti, M., Lemoli, R., Molteni, A., Busca,					
963	A., Cuneo, A., Romano, A., Giuliani, N., Galimberti, S., Corso, A., Morotti, A.,					
964	Falini, B., Billio, A., Gherlinzoni, F., Visani, G., Tisi, M.C., Tafuri, A., Tosi, P.,					
965	Lanza, F., Massaia, M., Turrini, M., Ferrara, F., Gurrieri, C., Vallisa, D., Martelli, M.,					
966	Derenzini, E., Guarini, A., Conconi, A., Cuccaro, A., Cudillo, L., Russo, D.,					
967	Ciambelli, F., Scattolin, A.M., Luppi, M., Selleri, C., Ortu La Barbera, E., Ferrandina,					
968	C., Di Renzo, N., Olivieri, A., Bocchia, M., Gentile, M., Marchesi, F., Musto, P., Endorigi, A. P., Candoni, A., Vanditti, A., Faya, C., Binto, A., Galiani, B., Bigagaji, J.					
969	Federici, A.B., Candoni, A., Venditti, A., Fava, C., Pinto, A., Galieni, P., Rigacci, L., Armiente D. Bang F. Oberti M. Zennesodi P. Viego C. Frenchi M. Grossi					
970 071	Armiento, D., Pane, F., Oberti, M., Zappasodi, P., Visco, C., Franchi, M., Grossi,					
971	P.A., Bertù, L., Corrao, G., Pagano, L., Corradini, P., 2020. Clinical characteristics					

972	and risk factors associated with COVID-19 severity in patients with haematological
973	malignancies in Italy: a retrospective, multicentre, cohort study. The Lancet
974	Haematology 7, e737–e745. https://doi.org/10.1016/S2352-3026(20)30251-9
975	Péron, J., Cropet, C., Tredan, O., Bachelot, T., Ray-Coquard, I., Clapisson, G., Chabaud, S.,
976	Philip, I., Borg, C., Cassier, P., Labidi Galy, I., Sebban, C., Perol, D., Biron, P., Caux,
977	C., Menetrier-Caux, C., Blay, JY., 2013. CD4 lymphopenia to identify end-of-life
978	metastatic cancer patients. European Journal of Cancer 49, 1080–1089.
979	https://doi.org/10.1016/j.ejca.2012.11.003
980	Pontelli, M.C., Castro, I.A., Martins, R.B., Veras, F.P., Serra, L.L., Nascimento, D.C.,
981	Cardoso, R.S., Rosales, R., Lima, T.M., Souza, J.P., Caetité, D.B., Lima, M.H.F. de,
982	Kawahisa, J.T., Giannini, M.C., Bonjorno, L.P., Lopes, M.I.F., Batah, S.S., Siyuan, L.,
983	Assad, R.L., Almeida, S.C.L., Oliveira, F.R., Benatti, M.N., Pontes, L.L.F., Santana,
984	R.C., Vilar, F.C., Martins, M.A., Cunha, T.M., Calado, R.T., Alves-Filho, J.C.,
985	Zamboni, D.S., Fabro, A., Louzada-Junior, P., Oliveira, R.D.R., Cunha, F.Q., Arruda,
986	E., 2020. Infection of human lymphomononuclear cells by SARS-CoV-2. bioRxiv
987	2020.07.28.225912. https://doi.org/10.1101/2020.07.28.225912
988	Puleston, D.J., Zhang, H., Powell, T.J., Lipina, E., Sims, S., Panse, I., Watson, A.S.,
989	Cerundolo, V., Townsend, A.R., Klenerman, P., Simon, A.K., 2014. Autophagy is a
990	critical regulator of memory CD8(+) T cell formation. Elife 3.
991	https://doi.org/10.7554/eLife.03706
992	Q, W., Q, C., H, Z., B, Y., X, H., Y, Z., X, Y., Mlk, C., C, X., 2020. Clinical outcomes of
993	coronavirus disease 2019 (COVID-19) in cancer patients with prior exposure to
994	immune checkpoint inhibitors. Cancer Commun (Lond) 40, 374–379.
995	https://doi.org/10.1002/cac2.12077
996	Rd, S., Lj, O., Mj, S., 2011. Cancer immunoediting: integrating immunity's roles in cancer
997	suppression and promotion [WWW Document]. Science (New York, N.Y.).
998	https://doi.org/10.1126/science.1203486
999	Robilotti, E.V., Babady, N.E., Mead, P.A., Rolling, T., Perez-Johnston, R., Bernardes, M.,
1000	Bogler, Y., Caldararo, M., Figueroa, C.J., Glickman, M.S., Joanow, A., Kaltsas, A.,
1001	Lee, Y.J., Lucca, A., Mariano, A., Morjaria, S., Nawar, T., Papanicolaou, G.A.,
1002	Predmore, J., Redelman-Sidi, G., Schmidt, E., Seo, S.K., Sepkowitz, K., Shah, M.K.,
1003	Wolchok, J.D., Hohl, T.M., Taur, Y., Kamboj, M., 2020. Determinants of COVID-19
1004	disease severity in patients with cancer. Nat Med 26, 1218–1223.
1005	https://doi.org/10.1038/s41591-020-0979-0
1006	Rugge, M., Zorzi, M., Guzzinati, S., 2020. SARS-CoV-2 infection in the Italian Veneto
1007	region: adverse outcomes in patients with cancer. Nature Cancer 1, 784–788.
1008	https://doi.org/10.1038/s43018-020-0104-9
1009	Sanmamed, M.F., Perez-Gracia, J.L., Schalper, K.A., Fusco, J.P., Gonzalez, A., Rodriguez-
1010	Ruiz, M.E., Oñate, C., Perez, G., Alfaro, C., Martín-Algarra, S., Andueza, M.P.,
1011	Gurpide, A., Morgado, M., Wang, J., Bacchiocchi, A., Halaban, R., Kluger, H., Chen,
1012	L., Sznol, M., Melero, I., 2017. Changes in serum interleukin-8 (IL-8) levels reflect
1013	and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung
1014	cancer patients. Annals of Oncology 28, 1988–1995.
1015	https://doi.org/10.1093/annonc/mdx190
1016	Schierwagen, R., Alvarez-Silva, C., Servant, F., Trebicka, J., Lelouvier, B., Arumugam, M.,
1017	2020. Trust is good, control is better: technical considerations in blood microbiome
1018	analysis. Gut 69, 1362–1363. https://doi.org/10.1136/gutjnl-2019-319123
1019	Sheng, L., Jena, P.K., Hu, Y., Liu, HX., Nagar, N., Kalanetra, K.M., French, Samuel
1020	William, French, Samuel Wheeler, Mills, D.A., Wan, YJ.Y., 2017. Hepatic

1021	inflammation caused by dysregulated bile acid synthesis is reversible by butyrate					
1022	supplementation. J Pathol 243, 431–441. https://doi.org/10.1002/path.4983					
1023	Shlomai, A., Ben-Zvi, H., Glusman Bendersky, A., Shafran, N., Goldberg, E., Sklan, E.H.,					
1024	2020. Nasopharyngeal viral load predicts hypoxemia and disease outcome in admitted					
1025	COVID-19 patients. Critical Care 24, 539. https://doi.org/10.1186/s13054-020-03244-					
1026	3					
1027	Silvin, A., Chapuis, N., Dunsmore, G., Goubet, AG., Dubuisson, A., Derosa, L., Almire, C.,					
1028	Hénon, C., Kosmider, O., Droin, N., Rameau, P., Catelain, C., Alfaro, A., Dussiau, C.,					
1029	Friedrich, C., Sourdeau, E., Marin, N., Szwebel, TA., Cantin, D., Mouthon, L.,					
1030	Borderie, D., Deloger, M., Bredel, D., Mouraud, S., Drubay, D., Andrieu, M.,					
1031	Lhonneur, AS., Saada, V., Stoclin, A., Willekens, C., Pommeret, F., Griscelli, F., Ng,					
1032	L.G., Zhang, Z., Bost, P., Amit, I., Barlesi, F., Marabelle, A., Pène, F., Gachot, B.,					
1033	André, F., Zitvogel, L., Ginhoux, F., Fontenay, M., Solary, E., 2020. Elevated					
1034	Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild					
1035	COVID-19. Cell 182, 1401-1418.e18. https://doi.org/10.1016/j.cell.2020.08.002					
1036	Song, X., Sun, X., Oh, S.F., Wu, M., Zhang, Y., Zheng, W., Geva-Zatorsky, N., Jupp, R.,					
1037	Mathis, D., Benoist, C., Kasper, D.L., 2020. Microbial bile acid metabolites modulate					
1038	gut ROR γ + regulatory T cell homeostasis. Nature 577, 410–415.					
1039	https://doi.org/10.1038/s41586-019-1865-0					
1040	Sterlin, D., Mathian, A., Miyara, M., Mohr, A., Anna, F., Claer, L., Quentric, P., Fadlallah, J.,					
1041	Ghillani, P., Gunn, C., Hockett, R., Mudumba, S., Guihot, A., Luyt, CE., Mayaux, J.,					
1042	Beurton, A., Fourati, S., Lacorte, JM., Yssel, H., Parizot, C., Dorgham, K.,					
1043	Charneau, P., Amoura, Z., Gorochov, G., 2020. IgA dominates the early neutralizing					
1044	antibody response to SARS-CoV-2. medRxiv 2020.06.10.20126532.					
1045	https://doi.org/10.1101/2020.06.10.20126532					
1046	Takahashi, T., Ellingson, M.K., Wong, P., Israelow, B., Lucas, C., Klein, J., Silva, J., Mao,					
1047	T., Oh, J.E., Tokuyama, M., Lu, P., Venkataraman, A., Park, A., Liu, F., Meir, A.,					
1048	Sun, J., Wang, E.Y., Casanovas-Massana, A., Wyllie, A.L., Vogels, C.B.F., Earnest,					
1049	R., Lapidus, S., Ott, I.M., Moore, A.J., Shaw, A., Fournier, J.B., Odio, C.D.,					
1050	Farhadian, S., Cruz, C.D., Grubaugh, N.D., Schulz, W.L., Ring, A.M., Ko, A.I., Omer,					
1051	S.B., Iwasaki, A., 2020. Sex differences in immune responses that underlie COVID-19					
1052	$\frac{1}{10000000000000000000000000000000000$					
1053	disease outcomes. Nature 1–6. https://doi.org/10.1038/s41586-020-2700-3					
1054	Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P.,					
100 1						
1055	Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P.,					
	Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B.,					
1055	Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin,					
1055 1056	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. 					
1055 1056 1057	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 					
1055 1056 1057 1058	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., 					
1055 1056 1057 1058 1059	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., 					
1055 1056 1057 1058 1059 1060	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired 					
1055 1056 1057 1058 1059 1060 1061 1062	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. 					
1055 1056 1057 1058 1059 1060 1061	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. https://doi.org/10.1128/mBio.02243-20 					
1055 1056 1057 1058 1059 1060 1061 1062 1063	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. 					
1055 1056 1057 1058 1059 1060 1061 1062 1063 1064	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. https://doi.org/10.1128/mBio.02243-20 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., 					
1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. https://doi.org/10.1128/mBio.02243-20 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., 					
1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. https://doi.org/10.1128/mBio.02243-20 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Ehmann, R., Zwirglmaier, K., Drosten, C., Wendtner, C., 					
1055 1056 1057 1058 1059 1060 1061 1062 1063 1064 1065 1066 1067	 Westblade, L.F., Brar, G., Pinheiro, L.C., Paidoussis, D., Rajan, M., Martin, P., Goyal, P., Sepulveda, J.L., Zhang, L., George, G., Liu, D., Whittier, S., Plate, M., Small, C.B., Rand, J.H., Cushing, M.M., Walsh, T.J., Cooke, J., Safford, M.M., Loda, M., Satlin, M.J., 2020. SARS-CoV-2 Viral Load Predicts Mortality in Patients with and without Cancer Who Are Hospitalized with COVID-19. Cancer Cell. https://doi.org/10.1016/j.ccell.2020.09.007 Westmeier, J., Paniskaki, K., Karaköse, Z., Werner, T., Sutter, K., Dolff, S., Overbeck, M., Limmer, A., Liu, J., Zheng, X., Brenner, T., Berger, M.M., Witzke, O., Trilling, M., Lu, M., Yang, D., Babel, N., Westhoff, T., Dittmer, U., Zelinskyy, G., 2020. Impaired Cytotoxic CD8+ T Cell Response in Elderly COVID-19 Patients. mBio 11. https://doi.org/10.1128/mBio.02243-20 Wölfel, R., Corman, V.M., Guggemos, W., Seilmaier, M., Zange, S., Müller, M.A., Niemeyer, D., Jones, T.C., Vollmar, P., Rothe, C., Hoelscher, M., Bleicker, T., Brünink, S., Schneider, J., Ehmann, R., Zwirglmaier, K., Drosten, C., Wendtner, C., 2020. Virological assessment of hospitalized patients with COVID-2019. Nature 581, 					

1071	disease 2019(COVID-19) by postmortem needle autopsy]. Zhonghua Bing Li Xue Za
1072	Zhi 49, 576–582. https://doi.org/10.3760/cma.j.cn112151-20200401-00278
1073	Yeoh, Y.K., Zuo, T., Lui, G.CY., Zhang, F., Liu, Q., Li, A.Y., Chung, A.C., Cheung, C.P.,
1074	Tso, E.Y., Fung, K.S., Chan, V., Ling, L., Joynt, G., Hui, D.SC., Chow, K.M., Ng,
1075	S.S.S., Li, T.CM., Ng, R.W., Yip, T.C., Wong, G.LH., Chan, F.K., Wong, C.K.,
1076	Chan, P.K., Ng, S.C., 2021. Gut microbiota composition reflects disease severity and
1077	dysfunctional immune responses in patients with COVID-19. Gut.
1078	https://doi.org/10.1136/gutjnl-2020-323020
1079	Zhang, H., Alsaleh, G., Feltham, J., Sun, Y., Napolitano, G., Riffelmacher, T., Charles, P.,
1080	Frau, L., Hublitz, P., Yu, Z., Mohammed, S., Ballabio, A., Balabanov, S., Mellor, J.,
1081	Simon, A.K., 2019. Polyamines Control eIF5A Hypusination, TFEB Translation, and
1082	Autophagy to Reverse B Cell Senescence. Mol Cell 76, 110-125.e9.
1083	https://doi.org/10.1016/j.molcel.2019.08.005
1084	Ziegler, C.G.K., Allon, S.J., Nyquist, S.K., Mbano, I.M., Miao, V.N., Tzouanas, C.N., Cao,
1085	Y., Yousif, A.S., Bals, J., Hauser, B.M., Feldman, J., Muus, C., Wadsworth, M.H.,
1086	Kazer, S.W., Hughes, T.K., Doran, B., Gatter, G.J., Vukovic, M., Taliaferro, F., Mead,
1087	B.E., Guo, Z., Wang, J.P., Gras, D., Plaisant, M., Ansari, M., Angelidis, I., Adler, H.,
1088	Sucre, J.M.S., Taylor, C.J., Lin, B., Waghray, A., Mitsialis, V., Dwyer, D.F.,
1089	Buchheit, K.M., Boyce, J.A., Barrett, N.A., Laidlaw, T.M., Carroll, S.L., Colonna, L.,
1090	Tkachev, V., Peterson, C.W., Yu, A., Zheng, H.B., Gideon, H.P., Winchell, C.G., Lin,
1091	P.L., Bingle, C.D., Snapper, S.B., Kropski, J.A., Theis, F.J., Schiller, H.B., Zaragosi,
1092	LE., Barbry, P., Leslie, A., Kiem, HP., Flynn, J.L., Fortune, S.M., Berger, B.,
1093	Finberg, R.W., Kean, L.S., Garber, M., Schmidt, A.G., Lingwood, D., Shalek, A.K.,
1094	Ordovas-Montanes, J., HCA Lung Biological Network. Electronic address: lung-
1095	network@humancellatlas.org, HCA Lung Biological Network, 2020. SARS-CoV-2
1096	Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells
1097	and Is Detected in Specific Cell Subsets across Tissues. Cell 181, 1016-1035.e19.
1098	https://doi.org/10.1016/j.cell.2020.04.035
1099	

1101 Figure Legends

1102

Figure 1. Prolonged duration of SARS-CoV-2 RNA shedding correlated with high viral load and COVID-19 severity in patients with cancer.

1105 A. Graphical schema of cohorts and patients' accrual. B. Proportion of patients with cancer 1106 from translational research (TR) (Cancer_FR1_TR, n=35, magenta area) or healthcare 1107 workers (HCW, n=45, blue area) by days of RT-qPCR positivity. Vertical dashed line at 40 days represents the 95th percentile of HCW and the median of positivity of patients with 1108 1109 cancer. C. Kaplan Meier curves of time to negative RT-qPCR in HCW (n=45, blue dotted lines) and patients with cancer (Cancer_FR1_TR, n=35, magenta continuous lines). D. 1110 1111 COVID-19+ cancer bearing or history of cancer (+) and cancer-free (-) individuals from FR2 1112 treated with hydroxychloroquine +/-azithromycine: number (percentages) of patients with RT-qPCR positivity beyond 16 days (90th percentile of the cancer-free population of FR2). **E.** 1113 1114 Number (percentages) of HCW, Cancer FR1 patients (Cancer FR1 TR) or Canadian patients 1115 with cancer (Cancer CA) with short, intermediate (grouped in short term viral RNA 1116 shedding, SVS) and prolonged (long term viral RNA shedding, LVS) viral RNA shedding 1117 (E), according to the presence/absence of viral symptoms (symptomatic, Sym, vs 1118 asymptomatic, Asym) (F), diagnosis of hematological (H) versus solid (S) malignancy (G), 1119 and cancer staging (localized (L), locally advanced (LA), metastatic (M)) (H). I. Number 1120 (percentages) of Cancer_FR1 patients (from translational research and clinical routine), 1121 Cancer_FR2 patients (Cancer_FR2) or Canadian patients with cancer (Cancer_CA) divided in 1122 SVS and LVS and regarding their respective COVID-19 severity. J. Spearman correlation 1123 between Cycle threshold (Ct) for the RT-qPCR amplification of genes encoding proteins of 1124 SARS-CoV-2 replication-transcription complex at diagnosis and duration of RT-qPCR 1125 positivity for Cancer FR1 (from translational research and clinical routine), each dot 1126 representing one sample/patient. K-L. Ct values for the RT-qPCR amplification of genes 1127 encoding proteins of SARS-CoV-2 replication-transcription complex in nasopharyngeal 1128 swabs performed at diagnosis in SVS versus LVS in Cancer_FR1_TR and CR and 1129 Cancer FR2 (K), and dynamics over time from day 0 up to day 80 after inclusion in SVS 1130 (n=33 samples, n=28 patients, orange dots) versus LVS (57 samples, n=17 patients, purple 1131 dots) in Cancer FR1 (from translational research and clinical routine) (L). Each line 1132 represents one patient. M. Redundancy statistical analysis (RDA) of the cancer and viral 1133 related-clinical factors accounting for the variance of SARS-CoV-2 viral shedding status. 1134 Clinical components were influenced by the virus shedding (SVS versus COVID-19 negative,

1135 *p*=0.037; LVS *versus* COVID-19 negative, *p*=0.0010), COVID severity (mild *versus* COVID-

1136 19 negative, p=0.0030; moderate versus COVID-19 negative, p=0.0574; severe versus

1137 COVID-19 negative, p not computable), age (p=0.0514), hematological rather than solid

1138 malignancy (hematological versus solid, p=0.001), metastatic status (p=0.0059), and Ct

values at diagnosis ($\square 25 \ versus < 25, p=0.0738$). Chi-square tests with *p<0.05, **p<0.01,

- 1140 ****p*<0.001, *****p*<0.0001.
- 1141

Figure 2. Immunotypes associated with prolonged viral RNA shedding in patients withcancer.

1144 **A.** Volcano plot of the differential cellular and soluble immune parameters contrasting short 1145 term viral RNA shedding (SVS) versus long term viral RNA shedding (LVS) during the first 1146 20 days of symptoms. Volcano plot was generated computing for each immune factor: i) the 1147 log2 of fold change among the mean relative percentages after normalization in SVS versus 1148 LVS (x axis); ii) the log10 of p values deriving from Wilcoxon test calculated on relative 1149 percentages in absolute values (y axis). Black and red dots are considered non-significant 1150 (p < 0.05) or significant (p > 0.05), respectively. **B-F.** Temporal changes and correlation of 1151 blood leukocyte parameters measured by high dimensional spectral flow cytometry (**B-D**) and 1152 soluble factors IFN α 2a and anti-SARS-CoV-2 IgG (E, F) in various phases of COVID-19 1153 presentation (no virus infection (Ctls, grey dots), asymptomatic viral infection (Asym, light 1154 blue dots), symptomatic viral infection examined in the first 20 days (≤20d) or after 20 days 1155 (>20d) of symptoms with those experiencing Short term Viral RNA Shedding (SVS, orange 1156 dots) or Long term Viral RNA Shedding (LVS, purple dots) and RT-qPCR negative COVID-1157 19 patients in the convalescent phase (Recovery, green dots or circled dots) (supplementary material, Figure 1). Box plots display a group of numerical data through their 3rd and 1st 1158 1159 quartiles (box), mean (central band), minimum and maximum (whiskers). Each dot represents 1160 one sample, each patient being drawn 1-3 times. Statistical analyses used one-way ANOVA 1161 with Kenward-Roger method to take into account the number of specimen/patient: *p < 0.05, 1162 **p < 0.01, ***p < 0.001, ****p < 0.0001. **B-D.** Percentages of neutrophils that do not express 1163 either CD101 and/or CD10 and lost CD16 within the gate of CD45⁺CD56⁻CD3⁻CD19⁻CD15⁺ 1164 cells (**B**, upper panel). Spearman correlation between the percentage of immature neutrophils 1165 (CD10^{+/-}CD101^{+/-}CD16⁻) measured within the first 20 days of symptoms with the duration of 1166 SARS-CoV-2 RT-qPCR positivity (**B**, lower panel). C-D. Percentages of CD38⁺ICOS⁺ 1167 among $CXCR5^+PD-1^+$ non-naive $CD4^+$ (C, left panel), plasmablasts defined as CD19^{low}CD38^{high}CD27⁺ within the CD19⁺ gate (**C, right panel**), double negative IgD⁻CD27⁻ 1168

1169 among $CD19^+$ cells (**D**, left panel) and their Spearman correlation when measured within the 1170 first 20 days of symptoms with the duration of SARS-CoV-2 RT-qPCR positivity (D, right 1171 panel). E. Ultrasensitive electrochemiluminescence assay to monitor the serum 1172 concentrations of IFNα2a (E, left panel) in a kinetic fashion (E, right panel). Each line and 1173 dot represent one patient and one sample, respectively and dashed line represents the median 1174 value of controls. F. Spearman correlation between the serum IFN α 2a values measured in 1175 symptomatic patients with IgG titers against SARS-CoV-2 S1-RBD considered as continuous 1176 variables (F, left panel). The raw data are represented in the right panel at both time points 1177 for each group of patients.

1178

Figure 3. Lymphopenia and high viral load are dismal prognosis factors for overall survival in cancer patients in the first and second surge of the pandemic.

1181 A. Spearman correlation between the absolute lymphocyte counts (ALC) of Cancer FR1 1182 (from translational research and clinical routine), with the duration of SARS-CoV-2 RT-1183 qPCR positivity (only evaluable patients for both factors, n=69 patients). B-C. ALC of 1184 Cancer_FR1 (from translational research and clinical routine) in SVS (n=37 patients) versus 1185 LVS (n=22 patients) subsets (**B**, left panel) or SARS-CoV-2-cycle threshold (Ct) > 25 (n=21 1186 patients) versus Ct < 25 (n=29 patients) (**B**, right panel) monitored during the COVID-19 1187 pandemic ("PER", between -4 and +7 days of the disease diagnosis by RT-qPCR), between 1188 210 and 12 days before the symptom onset of COVID-19 ("PRE") or within the recovery 1189 period (between 0 and 123 days after negative RT-qPCR) ("POST") at Gustave Roussy, with 1190 calculation of the reduction between "PRE" and during COVID-19 (C). One patient defined 1191 as outlier (at 215%) by ROUT method was excluded from the LVS group for the analysis. 1192 Each line and dot represents one patient and one sample. Statistical analyses used one-way 1193 ANOVA (paired and unpaired) with Kenward-Roger method taking into account the number 1194 of specimen/patient (B): p<0.05, p<0.01, p<0.01, p<0.001, p<0.001, p<0.000 and Mann-Whitney 1195 (C): *p<0.01. **D**. Kaplan Meier curve and Cox regression analysis of overall survival of 1196 cancer patients from the Discovery (1st surge) cohort (Cancer FR1+Cancer FR3), all stages 1197 included, according to ALC and Ct value at diagnosis. Refer to Table 1 for patient 1198 characteristics. E. Multivariate Cox regression analysis stratified for the cohort and adjusted 1199 for age, ECOG status, gender and metastatic and/or hematological status of cancer patients 1200 from the Discovery (1st surge) cohort (Cancer_FR1+Cancer_FR3). F. Kaplan Meier curve 1201 and Cox regression analysis of overall survival of cancer patients from Validation (2nd surge)

1202 cohort (Cancer_FR1+Cancer_FR3), all stages included, according to ALC and Ct value at1203 diagnosis. Refer to Table 1 for patient characteristics.

1204

1205 Figure 4. Prolonged viral shedding is associated with T cell exhaustion.

1206 **A.** Spearman correlation matrix focusing on the most significant immune variables and serum 1207 analytes monitored within the first 20 days of symptoms in patients diagnosed with COVID-1208 19 in the Cancer_FR1_TR cohort. Stars indicate significant values (p < 0.05) for positive (red) 1209 or negative (blue) correlations. **B.** Percentages of PD-1 expressing cells within the non-naive 1210 $CD8^+CD3^+$ population (**B**, upper panel), monitoring in various phases of COVID-19 1211 presentation (no virus infection (Ctls, grey dots), asymptomatic viral infection (Asym, light 1212 blue dots), symptomatic viral infection examined in the first 20 days ($\leq 20d$) or after 20 days 1213 (>20d) of symptoms with those experiencing Short term Viral RNA Shedding (SVS, orange 1214 dots) or Long term Viral RNA Shedding (LVS, purple dots) and RT-qPCR negative COVID-1215 19 patients in the convalescent phase (Recovery, green dots or circled dots) among 1216 Cancer FR1 TR (B, middle panel) and Spearman correlation with the duration of SARS-1217 CoV-2 RT-qPCR positivity measured within the first 20 days of symptoms (**B**, lower panel). 1218 C. Percentages of subsets co-expressing PD-1 and Granzyme B (C, left panel) or Granzyme B and FasL (C, right panel) in non-naïve $CD8^+$. D. Percentage of PD-1⁺ and Granzyme B⁺ 1219 within the non-naïve CD8⁺ expressing Eomes^{high}TCF-1^{high} gate (**D**, left panel) and Spearman 1220 1221 correlation between this ratio measured within the first 20 days of symptoms with the duration 1222 of SARS-CoV-2 RT-qPCR positivity (D, right panel). Box plots display a group of numerical data through their 3rd and 1st quartiles (box), mean (central band), minimum and 1223 1224 maximum (whiskers). Each dot represents one sample, each patient being drawn 1-3 times. 1225 Statistical analyses used one-way ANOVA with Kenward-Roger method to take into account 1226 the number of specimen/patients: *p < 0.05, **p < 0.01, ***p < 0.001. Each line and dot 1227 represents one patient and one sample, respectively (B, middle panel).

1228

Figure 5. Lymphopenia and prolonged viral shedding are associated with perturbationsof the polyamine and biliary acid pathways.

1231 **A.** Volcano plot identifying statistically different serum metabolites between patients 1232 experiencing Short term Viral RNA Shedding (SVS) and those experiencing Long term Viral 1233 RNA Shedding (LVS) in Cancer_FR1_TR cohort. Metabolites significantly different between 1234 both groups are in red and annotated (p<0.05, FC>0.5). **B.** Levels of murideoxycholic acid 1235 according to the duration of viral shedding in Cancer FR1 TR (**left panel**) and Spearman

1236 correlation with absolute lymphocyte count (ALC) (**right panel**). The color code corresponds 1237 to the category of cycle threshold (Ct) and ALC at diagnosis. C-D. Serum concentrations of 1238 deoxycholic acid according to the duration of viral shedding in Cancer FR1 TR (C) and the 1239 severity of COVID-19 infection in cancer free individuals (D). E. Waterfall plot of 1240 Spearman's correlation coefficient (r_s) between ALC and 221 metabolites in the serum of 1241 patients diagnosed positive for COVID-19. F. N1, N8-diacetylspermidine relative abundance 1242 in controls, SVS and LVS patients in the Cancer_FR1 cohort, that is negatively correlated 1243 with the ALC. The color code corresponds to the category of cycle threshold (Ct) and ALC at 1244 diagnosis. G. Levels of N1, N8-diacetylspermidine in non-cancer COVID-19 patients 1245 according the clinical severity compared to COVID19 negative controls (Ctls) (p<0.0001) (G, 1246 left panel), that are negatively correlated with the absolute lymphocyte count (ALC) (G, **right panel**). Box plots display a group of numerical data through their 3rd and 1st quartiles 1247 1248 (box), mean (central band), minimum and maximum (whiskers). Each dot represents one 1249 sample, each patient being drawn once for cancer free individuals and 1-2 times for cancer 1250 patients. Statistical analyses used one-way ANOVA with Kenward-Roger method to take into 1251 account the number of specimen/patient (B, left panel, C-E, left panel): *p<0.05, **p<0.01), 1252 non-parametric unpaired Wilcoxon test (Mann-Whitney) for each two-group comparison: 1253 p < 0.05, p < 0.01, p < 0.001, p < 0.001, p < 0.0001

1254

Figure 6. Lymphopenia and prolonged viral shedding are associated with blood recirculation of Enterobacteriaceae and Micrococcaceae DNA.

1257 **A.** Stacked bar charts showing the relative abundance of bacterial families obtained by 16S 1258 sequencing of the whole blood samples in patients experiencing Short term Viral RNA 1259 Shedding (SVS) and Long-term Viral RNA Shedding (LVS) among Cancer_FR1_TR. Only 1260 the top 15 most abundant bacterial families are represented (the others are in the category 1261 "Other"). B. Linear discriminant analysis effect size (LEfSe) analysis displaying linear 1262 discriminant analysis score (LDA) of the blood bacterial taxa differentially recovered from 1263 SVS (orange) versus LVS (purple) patients (p < 0.05 with Mann–Whitney test between the 1264 two groups of patients). C. Mean (bar plots, +/- SEM) and individual values (dot plots) of 1265 relative proportions of Enterobacteriaceae (C, left panel) and Micrococcaceae (C, right 1266 panel) family members in SARS-CoV-2 positive and Recovered patients. Significance 1267 between SVS and LVS patients was evaluated using Mann-Whitney test (*p < 0.05). D-E. 1268 Spearman correlations between the relative proportions of Enterobacteriaceae with paired 1269 concentrations of CCL22 in serum (**D**) and with paired percentages of Granzyme B

(GzB)⁺PD-1⁺ in Eomes^{hi}TCF-1^{hi} non-naïve CD8⁺ measured in blood (E). F. Idem as in A. 1270 1271 considering segregating the cohort in two groups; ALC > 0.8G/L and/or Ct > 25 patients 1272 versus ALC < 0.8G/L & Ct < 25 patients. G. LEfSe analysis displaying LDA score of the 1273 blood bacterial taxa significantly increased in ALC > 0.8G/L and/or Ct > 25 patients (grey) 1274 and ALC < 0.8G/L & Ct < 25 patients (red). The displayed bacterial taxa are significantly 1275 different (*p < 0.05 with Mann–Whitney test) between the two groups of patients. **H.** Idem as 1276 in C segregating the cohort into the same two groups as in F. Significance between ALC > D1277 0.8G/L and/or Ct > 25 patients and ALC < 0.8G/L & Ct < 25 patients was evaluated using the 1278 Mann-Whitney test (*p < 0.05).

1279

1280

1281 **Table**

Table 1. Clinical characteristics of Cancer_FR1 and Cancer_FR3 patients from discovery and
 validation cohorts presenting cycle threshold below (Ct<25) or above 25 (Ct>25) and with (

1284 800/mm³) or without (> 800/mm³) lymphopenia at diagnosis (refer to Figure 3D-F).

1285

Abbreviations: BMI: Body Mass Index; COPD: Chronic Obstructive Pulmonary Disease; CR:
Clinical Routine; Ct: Cycle threshold; DM: Diabetes mellitus; H: Hematological
malignancies; ICU: Intensive Care Unit; n: number; NED: no evidence of disease; no:
number; PD: Progressive disease; PS: Performance Status; S: Solid tumors; SD/PR: Stable
disease/Partial response; TR: Translational Research; *in the 4 weeks before inclusion.

1291 Statistical analyses: ANOVA (Kruskal-Wallis)(#), Chi-Square or Fisher's exact tests.

[°]unknown for Cancer_FR3_discovery (n=26 patients), calculations with
Cancer_FR1_discovery, n=84.

1294 °*unknown for Cancer_FR3_validation (n=25 patients), calculations with
1295 Cancer_FR1_validation, n=91.

- 1296
- 1297
- 1298
- 1299

1300 Materials and methods

1301

1302 All cohorts (refer to Supplementary Material, Table 1)1303

1304 **Supplementary Material, Table 1.** List of all cohorts analysed in the study.

Cohorts	Hospital, City, country	Reference	Number of included patients (N) and number analysed (n) <u>DISCOVERY First surge:</u> N=473	EuDRACT ethical number
Cancer_FR1_TR (ONCOVID)	Gustave Roussy, Villejuif, France		N=52 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=35), Ct and ALC at diagnosis (n=34), High dimensional immunology (n=88), Multiplex cytokine arrays (n=88), anti-SARS-CoV-2 antibodies (n=87)	2020-001250-21
Cancer_FR1_CR	Gustave Roussy, Villejuif, France	Nat Cancer. 2020 Sept;1:965-975.	$\begin{tabular}{lllllllllllllllllllllllllllllllllll$	MR4911200520
нсw	Gustave Roussy, Villejuif, France		VALIDATION Second surge: N=170 COVID-19 ⁺ Ct and ALC at diagnosis (n=82) N=100 COVID-19 ⁺ Duration of SARS-CoV-2 RNA	MR004
Cancer_FR2 (cases) Non cancer (controls)	IHU Méditerranée Infections, Marseille, France IHU Méditerranée Infections, Marseille, France	TMID. 2020. Jul-Aug;36:101791.	shedding (n=45) N=175 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=99) N=350 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=198)	2020-021
Cancer_FR3 (ONCOVID-19)	Centre Léon Bérard, Lyon, France	Eur J Cancer. 2020 Nov; 139: 68–69. Eur J Cancer 2020 Oct;138:225-227. Eur J Cancer. 2020 Aug; 135: 242–250.	DIOVERY First surge: N=287 N=63 COVID-19 ⁺ Ct and ALC at diagnosis (n=26) Electronic Clinical files & virology VALIDATION Second surge: Ct and ALC at diagnosis (n=25)	ET20-069
Cancer_CA	Multicenter study, community COVID-19 versus nosocomial, Canada	EJC Cancer. 2020; Sept:139, 181–187	N=252 COVID-19 ⁺ Duration of SARS-CoV-2 RNA shedding (n=66)	MP-02- 2020- 8911 and H20- 00892
1303				

1207

1307 Cohorts for the duration of viral PCR positivity.

1308

1309 1/ Cancer_FR1_Translational Research (TR) (ONCOVID) clinical trial and regulatory 1310 approvals for translational research. Principles. Gustave Roussy Cancer Center sponsored 1311 the "ONCOVID" trial and collaborated with the academic authors on the design of the trial 1312 and on the collection, analysis, and interpretation of the data. Sanofi provided trial drugs. The 1313 trial was conducted in accordance with Good Clinical Practice guidelines and the provisions 1314 of the Declaration of Helsinki. All patients provided written informed consent. Protocol 1315 approval was obtained from an independent ethics committee (ethics protocol number 1316 EudraCT No: 2020-001250-21). The protocol is available with the full text of this article at 1317 https://clinicaltrials.gov/ct2/show/NCT04341207. Patients. ONCOVID eligible patients were 1318 adults fitted for, or under, or recently treated by chemotherapy and/or immune-checkpoint 1319 blockade for the treatment of solid tumors or hematological malignancies (Refer to Table 1 and Table S1). Patients diagnosed for COVID-19 from April 10th, 2020 to May 4th, 2020 were 1320 1321 included in the Discovery cohort and patients from May 5th, 2020 to November 25th, 2020 1322 were included in the Validation cohort. Trial design. Cancer patients were screened for 1323 SARS-CoV-2 virus carriage by nasopharyngeal sampling at every hospital visit. The presence 1324 of SARS-CoV-2 RNA was detected by RT-qPCR assay in a BSL-2 laboratory. Asymptomatic 1325 and symptomatic patients (i.e presenting with fever (t°>38°C) and/or cough and/or shortness of breath and/or headache and/or fatigue and/or runny nose and/or sore throat, 1326 1327 anosmy/agueusia) with a positive SARS-CoV-2 RT-qPCR test, shifted to the interventional 1328 phase (tailored experimental approach with Hydroxychloroquine and Azithromycin therapy in 1329 symptomatic SARS-CoV-2 positive subjects). Asymptomatic or symptomatic patients with 1330 negative SARS-CoV-2 RT-qPCR test continued their standard of care anti-cancer treatments. 1331 Repeated RT-qPCR for SARS-CoV-2 on nasopharyngeal swabs and blood samples were 1332 performed to monitor the status for SARS-CoV-2 and the immune response, respectively, in 1333 COVID-19 positive and negative patients. The COVID-19 severity was defined based on 1334 oxygen, imaging and hospitalization criteria. Patients with a mild COVID-19 disease had 1335 limited clinical symptoms not requiring scan or hospitalization; patients with a moderate 1336 COVID-19 disease were symptomatic with a dyspnea and radiological findings of pneumonia on thoracic scan requiring hospitalization and a maximum of 9L/min of oxygen; severe 1337 1338 patients had respiratory distress requiring intensive care and/or more than 9L/min of oxygen. 1339 Samples for translational research. Whole blood was used for high dimensional spectral 1340 flow cytometry analyses. Serum samples were used to monitor the concentrations of

1341 cytokines and chemokines release and to titer anti-SARS-CoV-2 IgG, M and A antibodies

1342 (see blood analysis section) (Supplementary Material Figure 1).

1343

1344 2/ Health Care Workers (HCW) of Cancer_FR1_TR.

1345 The part of the research including health care workers was conducted in compliance with 1346 General Data Protection Regulation (GDPR) and the French Data Protection Authority's 1347 recommendation about Data Protection in clinical researches. Gustave Roussy Data 1348 Protection Officer (DPO) has evaluated this project and sent to the principal investigator a 1349 formalized-operational action plan about data protection compliance: patient's information, 1350 security measures, good practices about pseudonymization, etc. All of the DPO's 1351 recommendations has been applied by the research team. Health care workers diagnosed for COVID-19 between 24th March and 24th April 2020 were included. Results of RT-gPCR, 1352 1353 cycle threshold, age, gender, and number of comorbidities were collected. Data from health 1354 care workers who refused to participate and/or with a cancer were excluded. In agreement 1355 with MR004 in France, we reported the series to the national information science and liberties 1356 commission.

1357

1358 3/ Second series of patients with cancer (Cancer FR2): CASE-CONTROL study. All comers 1359 spontaneously presenting at a general hospital for infectious diseases (IHU Méditerranée Infections, Marseille, FR) (Table S1) from February 27th, 2020 to December 15th, 2020 1360 composed of 996 COVID-19 patients. We performed a case-control study at a 1:2 paired ratio 1361 1362 where the 175 cancer patients (with a currently treated cancer or history of cancer) were 1363 matched with 350 cancer free individuals on age, gender, comorbidities relevant for COVID-1364 19. Of note, >75% received hydroxychloroquine and >96% received azithromycine (Table 1365 S1) (Amrane et al., 2020; Lagier et al., 2020). This study was approved by the IHU 1366 Méditerranée Infections review board committee (Méditerranée Infection N°: 2020-021).

1367

4/ Third series of cancer patients from Canada (Cancer_CA). We used 66 individuals from
the clinical cohort previously reported(Elkrief et al., 2020) for whom data were available
(Table S1). This study was conducted across eight Canadian institutions in Quebec and
British Columbia and was approved by the institutional ethics committee at each site (Ethics
number: MP-02- 2020-8911 and H20-00892).

1374 5/Fifth series of cancer patients, Cancer_FR1_Clinical Routine (CR). We used the clinical 1375 cohort previously reported(Albiges et al., 2020) (Table S1). In accordance with the French 1376 regulations, there was no requirement for ethical approval to be sought for this observational 1377 study, based on medical files. Patients diagnosed for COVID-19 from March 14th, 2020 to April 29th, 2020 were included in the Discovery cohort and from April 29th, 20 to November 1378 1379 25th, 2020 in the Validation cohort. This study was also declared to the Gustave Roussy 1380 Cancer Centre's data protection officer and registered on the website of the French Healthcare 1381 Data Institute (declaration number: MR4911200520).

1382

1383 Cohorts for the ALC and Ct value predictors: first surge and second surge of the1384 pandemic.

1385 1/ Cancer_FR1_Translational Research (TR) (ONCOVID) clinical trial and regulatory

1386 *approvals for translational research.* Among the 52 patients diagnosed for COVID-19 during

1387 the first surge (from April 10th, 2020 to May 4th, 2020), absolute lymphocyte count (ALC) and

1388 cycle threshold (Ct) were available for 34 patients whom were included in this cohort.

1389 Then, among the 18 patients included in ONCOVID during the second surge (from May 5th,

1390 2020 to November 25th, 2020), absolute lymphocyte count (ALC) and cycle threshold (Ct)
1391 were available for 9 patients whom were included in this cohort

1392

1393 2/ Cancer patients referred to the clinical routine (Cancer FR1 CR). In accordance with 1394 the French regulations, there was no requirement for ethical approval to be sought for this 1395 observational study, based on medical files. Among the 178 patients diagnosed for COVID-19 during the first surge (March 14th, 2020 to April 29th, 2020), ALC and Ct were available for 1396 50 patients whom were included in this cohort. Then, among 170 patients with cancer 1397 diagnosed for COVID-19 during the second surge (from May 5th, 2020 to November 25th, 1398 1399 2020), ALC and cycle threshold Ct were available for 82 patients whom were included in this 1400 cohort.

1401

3/ Cancer patients referred to the Centre Léon Bérard, Lyon, France (Cancer_FR3). The
PRE-ONCOVID-19 study was approved by the Institutional review board of the Centre Leon
Bérard on March 12th, 2020 (ET20-069). We used a subset of 25 patients included during the
first surge from March 5th, 2020 to May 4th, 2020 with available ALC and Ct values. We used
patients included during the second surge from October 1th, 2020 to December 5th, 2020
with available data.

1408

1410

1409 Patients from each cohort were classified using the same criteria.

1411 **RT-qPCR** analysis. SARS-CoV-2 diagnostic testing of clinical nasopharyngeal swabs or other samples by RT-qPCR was conducted from March 14th, 2020 to March 23th, 2020 at an 1412 outside facility using the Charité protocol. From March 23th, 2020 testing was performed 1413 1414 internally at the Gustave Roussy. The cycle thresholds were collected only for assays 1415 performed at Gustave Roussy. Nasopharyngeal swab samples were collected using flocked 1416 swabs (Sigma Virocult) and placed in viral transport media. SARS-CoV-2 RNA was detected 1417 using one of two available technics at Gustave Roussy: the GeneFinder COVID-19 Plus 1418 RealAmp kit (ELITech Group) targeting three regions (RdRp gene, nucleocapsid and envelope 1419 genes) on the ELITe InGenius (ELITech Group) or the multiplex real-time RT-PCR 1420 diagnostic kit (the Applied Biosystems TaqPath COVID-19 CE-IVD RT-PCR Kit) targeting 1421 three regions (ORF1ab, nucleocapsid and spike genes) with the following modifications. 1422 Nucleic acids were extracted from specimens using automated Maxwell instruments 1423 following the manufacturer's instructions (Maxwell RSC simplyRNA Blood Kit; AS1380; 1424 Promega). Real-time RT-PCR was performed on the QuantiStudio 5 Dx Real-Time PCR 1425 System (Thermo Fisher Scientific) in a final reaction volume of $20 \Box \mu l$, including $5 \Box \mu l$ of 1426 extracted nucleic acids according to the manufacturer instruction.

1427 The cut-off value of 25 for the cycle threshold was based on the median calculated on 1428 Cancer_FR1_TR and the mean calculated on Cancer_FR1_TR+CR.

1429 RT-PCR for subgenomic RNA (sgRNA) for SARS-CoV-2. We used the protocol 1430 previously described by Wölfel et al. in *Nature*, 2020. Briefly, the oligonucleotide sequence 1431 the follows: of leader specific primer was as sgLeadSARSCoV2-F; 1432 CGATCTCTTGTAGATCTGTTCTC, and the oligonucleotide sequence of the E primer was 1433 as follows: E_Sarbeco_R; ATATTGCAGCAGTACGCACAA. Briefly, 5 uL of RNA (>21 1434 ng) were used for the sgRNA RT-PCR assay with Superscript III one-step RT-PCR system 1435 with Platinum Taq Polymerase (Invitrogen, Darmstadt, Germany) with 400 nM concentration 1436 of each primer. Thermal cycling was set up as described. Finally, RT-PCR products for 1437 sgRNAs were analyzed on agarose gel 2%.

Evaluation of SARS-CoV-2 RNA shedding. The duration of viral shedding was defined as
the number of days from the first positive to the first negative RT-qPCR, after longitudinal
monitoring. In order to prevent an overvaluation of this duration, we considered in this

analysis only patients with an interval below 40 days between the last positive RT-qPCR and the first negative RT-qPCR. Six patients had one negative RT-qPCR followed by positive RTqPCR. We extend the duration to the second negative RT-qPCR for 3 patients with a cycle threshold below 35 for the gene coding replication-transcription complex and within 6 days after the first negative result.

1446 Absolute Lymphocyte Count (ALC). The absolute lymphocyte count was measured for the 1447 clinical routine using the Sysmex XN (Sysmex, Belgium). Values "PRE" were collected 1448 between 210 and 12 days before the symptom onset of COVID-19, values at diagnosis of the 1449 infection were collected between -4 and +7 days of the disease diagnosis by RT-qPCR, values 1450 "POST" were collected at the recovery time or later, meaning between 0 and 123 days after 1451 the first negative RT-qPCR. For the interpretation, the cut-off value for ALC was the median found in patients with high viral load at diagnosis (ALC=800/mm³). In parallel, we 1452 1453 considered this value as relevant according to the common terminology criteria for adverse 1454 events where grades of lymphopenia were assigned as following: grade 1 ALC < lower limit 1455 of normal to 800/mm3, grade 2 ALC < 800-500/mm3, and grade 3 ALC < 500-200/mm3.

1456 Blood tests. Sampling. Blood samples were drawn from patients enrolled in ONCOVID at 1457 Gustave Roussy Cancer Campus (Villejuif, France). Whole human peripheral blood was 1458 collected into sterile vacutainer tubes. Spectral flow cytometry. One hundred and twenty-one 1459 whole blood samples from 88 patients (Supplementary Material Figure 1) was mixed at a 1:1 1460 ratio with Whole Blood Cell Stabilizer (Cytodelics), incubated at room temperature for 10 1461 min and transferred to -80°C freezer to await analysis. These samples were secondarily 1462 thawed in a water bath set to +37°C. Cells were fixed at a ratio 1:1 with Fixation Buffer 1463 (Cytodelics, ratio 1:1) and incubated for 10 min at room temperature. Red blood cells were 1464 lysed by addition of 2 mL of Lysis Buffer (Cytodelics, ratio 1:4) at room temperature for 10 1465 min. White blood cells were washed with 2 mL of Wash Buffer (Cytodelics, ratio 1:5). Cells 1466 were resuspended in 100 µL extra-cellular antibody cocktail and incubated at room 1467 temperature for 15 min, then washed in Flow Cytometry Buffer (PBS containing 2% of fetal 1468 bovine serum and 2 mM EDTA). For intra-cellular labelling, a step of permeabilization was 1469 performed using 200 µL of eBioscience Foxp3 kit (ThermoFischer); cells were then incubated 1470 for 40 min at +4°C, washed in Perm Buffer (ThermoFischer) and resuspended in intra-cellular 1471 antibody cocktail. After incubation, cells were washed in Flow Cytometry Buffer and 1472 resuspended to proceed to the acquisition. All antibodies used are listed in Supplemental

1473 Material Table 2. Samples were acquired on CyTEK Aurora flow cytometer (Cytek 1474 Biosciences). 16S rDNA metagenomic profiling. DNA from blood was isolated and 1475 amplified in a strictly controlled environment at Vaiomer SAS (Labège, France) using a 1476 stringent contamination-aware approach as discussed previously (Anhê et al., 2020; Lluch et 1477 al., 2015; Païssé et al., 2016; Schierwagen et al., 2020). The microbial populations based on 1478 rDNA present in blood were determined using next-generation sequencing of V3-V4 variable 1479 regions of the 16S rRNA bacterial gene as previously described (Lluch et al., 2015). For each 1480 sample, a sequencing library was generated by addition of sequencing adapters. The joint pair 1481 length was set to encompass a 467 base pairs amplicon (using Escherichia coli 16S as a 1482 reference) with a 2×300 paired end MiSeq kit V3 (Illumina, San Diego, CA, USA). The 1483 detection of the sequencing fragments was performed using the MiSeq Illumina® technology. 1484 Targeted metagenomic sequences from microbiota were analysed using the bioinformatic 1485 pipeline from the FROGS guideline (Escudié et al., 2018). Briefly, the cleaning was done by 1486 removing amplicons without the two PCR primers (10% of mismatches were authorised), 1487 amplicons with at least one ambiguous nucleotide ('N'), amplicons identified as chimera 1488 (with vsearch v1.9.5), and amplicons with a strong similarity (coverage and identity $\geq 80\%$) 1489 with the phiX (library used as a control for Illumina sequencing runs). Clustering was 1490 produced in two passes of the swarm algorithm v2.1.6. The first pass was a clustering with an 1491 aggregation distance equal to 1. The second pass was a clustering with an aggregation 1492 distance equal to 3. Taxonomic assignment of amplicons into operational taxonomic units 1493 (OTUs) was produced by Blast+ v2.2.30+ with the Silva 134 Parc databank. To assess if the 1494 richness of microbiota was adequately captured by metagenomic sequencing, a rarefaction 1495 analysis was performed. To ensure a low background signal from bacterial contamination of 1496 reagents and consumables, two types of negative controls consisting of molecular grade water 1497 were added in an empty tube separately at the DNA extraction step and at the PCR steps and 1498 amplified and sequenced at the same time as the extracted DNA of the blood samples. The 1499 controls confirm that bacterial contamination was well contained in our pipeline and had a 1500 negligible impact on the taxonomic profiles of the samples of this study as published before 1501 (Anhê et al., 2020; Lluch et al., 2015; Païssé et al., 2016; Schierwagen et al., 2020). One 1502 sample has been excluded of the analyses for aberrant profile.

1503

Serum tests. Serums from 120 samples corresponding to 88 patients (Supplementary Material
Figure 1) were collected from whole blood after centrifugation at 600 g for 10 min at room
temperature and transferred to -80°C freezer to await analysis.

1507 Multiplex cytokine and chemokine measurements. Serum samples were centrifuged for 15 1508 min at 1,000 g, diluted 1:4, then monitored using the Bio-Plex ProTM Human Chemokine 1509 Panel 40-plex Assay (Bio-rad, ref: 171AK99MR2) according to the manufacturer's 1510 instructions. 40-plex cytokines and chemokines provided are: CCL1, CCL11, CCL13, 1511 CCL15, CCL17, CCL19, CCL2, CCL20, CCL21, CCL22, CCL23, CCL24, CCL25, CCL26, 1512 CCL27, CCL3, CCL7, CCL8, CX3CL1, CXCL1, CXCL10, CXCL11, CXCL12, CXCL13, 1513 CXCL16, CXCL2, CXCL5, CXCL6, CXCL8, CXCL9, GM-CSF, IFN-γ, IL-10, IL-16, IL-1β, 1514 IL-2, IL-4, IL-6, MIF, TNF- α . Acquisitions and analyses were performed on a Bio-Plex 200 1515 system (Bio-rad) and a Bio-Plex Manager 6.1 Software (Bio-rad), respectively. Soluble 1516 Calprotectin (diluted 1:100) and IFN- α 2a were analyzed using a R-plex Human Calprotectin 1517 Antibody Set (Meso Scale Discovery, ref: F21YB-3) and the ultra-sensitive assay S-plex 1518 Human IFN- α 2a kit (Meso Scale Discovery, ref: K151P3S-1), respectively, following 1519 manufacturer's instructions. Acquisitions and analyses of soluble Calprotectin and IFN- α 2a 1520 were performed on a MESOTM QuickPlex SQ120 reader and the MSD's Discovery 1521 Workbench 4.0. Each serum sample was assayed twice with the average value taken as the 1522 final result.

1523 Serology: Anti-SARS-CoV-2 immunoglobulins. Serum was collected from whole blood after 1524 centrifugation at 600 g for 10 min at room temperature and transferred to -80°C freezer to 1525 await analysis. Serological analysis SARS-CoV-2 specific IgA, IgM and IgG antibodies were 1526 measured in 119 serum samples from 87 patients (Supplementary Material Figure 1) with The 1527 Maverick TM SARS-CoV-2 Multi-Antigen Serology Panel (Genalyte Inc. USA) according to the manufacturer's instructions. The Maverick TM SARS-CoV-2 Multi-Antigen Serology 1528 1529 Panel (Genalyte Inc) is designed to detect antibodies to five SARS-CoV-2 antigens: 1530 nucleocapsid, Spike S1 RBD, Spike S1S2, Spike S2 and Spike S1 with in a multiplex format 1531 based on photonic ring resonance technology(Sterlin et al., 2020). This system detects and 1532 measure with good reproducibility changes in resonance when antibodies bind to their 1533 respective antigens in the chip. The instrument automates the assay. Briefly, 10µl of each 1534 serum samples were added in a sample well plate array containing required diluents and 1535 buffers. The plate and chip are loaded in the instrument. First the chip is equilibrated with the 1536 diluent buffer to get baseline resonance. Serum sample is then charged over the chip to bind specific antibodies to antigens present on the chip. Next, chip is washed to remove low 1537 1538 affinity binders. Finally, specific antibodies of patients are detected with anti-IgG or -IgA or -1539 IgM secondary antibodies.

1540 *Metabolomics analysis.* Samples were prepared as previously described (Danlos et al., In 1541 Press). Briefly, serum samples were mixed with ice-cold extraction mixture (methanol/water, 1542 9/1, v/v, with a mixture of internal standards), then centrifugated. Supernatants were collected 1543 for widely-targeted analysis of intracellular metabolites. GC/MS analysis. GC-MS/MS 1544 method was performed on a 7890B gas chromatography (Agilent Technologies, Waldbronn, 1545 Germany) coupled to a triple quadrupole 7000C (Agilent Technologies, Waldbronn, 1546 Germany) equipped with a high sensitivity electronic impact source (EI) operating in positive 1547 mode. Targeted analysis of bile acids. Targeted analysis was performed on a RRLC 1260 1548 system (Agilent Technologies, Waldbronn, Germany) coupled to a QTRAP 6500+ (Sciex) 1549 equipped with an electrospray source operating in negative mode. Gas temperature was set to 1550 450°C, with ion source gas 1 and 2 set to 30 and 70, respectively. Targeted analysis of 1551 polyamines. Targeted analysis was performed on a RRLC 1260 system (Agilent 1552 Technologies, Waldbronn, Germany) coupled to a QQQ 6410 (Agilent Technologies) 1553 equipped with an electrospray source operating in positive mode. The gas temperature was set 1554 to 350°C with a gas flow of 12 l/min. The capillary voltage was set to 3.5 kV. Targeted 1555 analysis of SCFA. Targeted analysis was performed on a RRLC 1260 system (Agilent 1556 Technologies, Waldbronn, Germany) coupled to a QQQ 6410 (Agilent Technologies) 1557 equipped with an electrospray source operating in negative mode. Gas temperature was set to 1558 350°C with a gas flow of 12 L/min. Capillary voltage was set to 4.0 kV. Pseudo-targeted 1559 analysis of intracellular metabolites. The profiling experiment was performed with a Dionex 1560 Ultimate 3000 UHPLC system (Thermo Scientific) coupled to a Q-Exactive (Thermo 1561 Scientific) equipped with an electrospray source operating in both positive and negative mode 1562 and full scan mode from 100 to 1200 m/z. The Q-Exactive parameters were: sheath gas flow 1563 rate 55 au, auxiliary gas flow rate 15 au, spray voltage 3.3 kV, capillary temperature 300°C, 1564 S-Lens RF level 55 V. The mass spectrometer was calibrated with sodium acetate solution 1565 dedicated to low mass calibration.

1566

Data analysis. *Spectral flow cytometry.* Fcs files were exported and analyzed using FlowJo software using the gating strategy showed in Supplementary material, Figure 2. Briefly, gates on CD45⁺, CD3⁺ or CD19⁺ from the myeloid, T cell and B panels, respectively, were exported in an fcs file. All exported gates from one panel were used to generate an UMAP(Becht et al., 2019). As shown on Supplementary material Figures 3 and 4, we used relative expression and manual gating strategy. For patients treated by anti-PD-1 monoclonal antibody, the gates including PD-1 were excluded of the analysis. For patients treated by anti-

1574 CD38 monoclonal antibody, the gates including CD38 were excluded of the analysis.
1575 *Representation of the results.* Data representation was performed with software R v3.3.3
1576 using tidyverse, dplyr, ggplot2, ggpubr, pheatmap, corrplot or Hmisc packages or GraphPad
1577 Prism 7.

1578

1579 Statistical analyses. Calculations and statistical tests were performed either with R v3.3.3 or 1580 Prism 7 (GraphPad, San Diego, CA, USA). Unless stated, p-values are two-sided with 95% 1581 confidence intervals for the reported statistic of interest. Individual data points representing 1582 the measurement from one patient are systematically calculated from the corresponding 1583 distribution. Biological parameters associated to statistically significant differences between 1584 groups were considered for the data visualization described below. Group comparison was 1585 performed using one-way ANOVA with the lmer function of the lme4 R package. The p-1586 values were computed with the Kenward-Roger method, available in the Imertest R package. 1587 Spearman correlations were computed using Hmisc and Pheatmap R package. Hierarchical 1588 clustering of the patient's factors was performed using using the hclust R package. The 1589 redundancy analysis (RDA) was performed using the vegan R package to explore the 1590 association between the clinical variables and the biological parameters correlation latent 1591 structure. The RDA performs variance decomposition such as principal component analysis, 1592 but including additional supervised components depending on the explanatory variables (e.g. 1593 clinical factors). The association of the clinical factors with the biological parameter 1594 correlation latent structure was tested using permutation test. Kaplan-Meier methodology was 1595 used to estimate the probability of overall survival as well as to visualize the median time of 1596 SARS-CoV-2 RNA shedding for each group (HCW and Cancer). One-way ANOVA (paired 1597 and unpaired) with Kenward-Roger method was used to calculate p-value between ALC 1598 among groups of viral RNA shedding and Ct values. Chi-Square, Fischer test were used to 1599 calculate the differences in proportion between groups. Comparing two groups, Mann-1600 Whitney test was used. Univariate analyses were performed with the Cox regression model. 1601 p < 0.05 was considered as significant. Multivariate Cox analysis was performed using the 1602 survival R package stratified for the cohort and adjusted for the age, ECOG performance 1603 status, gender and metastatic status and hematological malignancy.

1604

1606 Supplemental figure legends

1607

1608 Figure S1. Cancer_FR1_Translationnal Research patient clinical characteristics.

- 1609 A. Consort flow chart diagram of ONCOVID (Cancer_FR1_Translationnal Research (TR))
- 1610 patients at trial inclusion, delineating COVID-19 positive cases retained for the evaluation of
- 1611 duration of SARS-CoV-2 RNA shedding and cycle threshold (Ct) with absolute lymphocyte
- 1612 count (ALC) at diagnosis, and their controls for the translational research ancillary study
- 1613 (Cancer_FR1). B-G. Number (percentages) of patients with cancer diagnosed with COVID-
- 1614 19 and with hematological (H) versus solid (S) malignancy (B-C), presenting symptomatic
- 1615 (Sym) vs asymptomatic (Asym) infection (D-E), and at different stages of disease (localized
- 1616 (L), locally advanced (LA), metastatic (M)) of their cancer (**F-G**).
- 1617

1618 Figure S2. Reliability of the monitoring of viral shedding.

1619 Consort flow chart diagram of patients with cancer (A) and healthcare workers (HCW) (B)

diagnosed with COVID-19 retained for the evaluation of duration of SARS-CoV-2 RNAshedding in the ancillary study presented in Figure 1.

1622

Figure S3. Patient clinical characteristics in a second series of patients with cancer at Gustave Roussy, Cancer_FR1_Clinical Routine.

1625 A. Consort flow chart diagram of second series patients with cancer (Cancer_FR1_Clinical 1626 Routine (CR)) diagnosed with COVID-19 at Gustave Roussy and monitored in clinical routine during the pandemic (March 14th - April 29th) retained for the evaluation of duration 1627 1628 of SARS-CoV-2 RNA shedding and cycle threshold (Ct) with absolute lymphocyte count 1629 (ALC) at diagnosis. B-G. Proportions of COVID-19 cancer patients with hematological (H) 1630 vs solid malignancy (S) (B-C), presenting symptomatic (Sym) vs asymptomatic (Asym) 1631 infection (D-E), and at different stages of disease (localized (L), locally advanced (LA), 1632 metastatic (M)) of their cancer (**F-G**).

Figure S4. Immunotypes associated with prolonged viral RNA shedding in patients withcancer.

1635 Temporal changes and correlation of blood leukocyte parameters measured by high 1636 dimensional spectral flow cytometry and multiple soluble factors in various phases of 1637 COVID-19 presentation (no virus infection (Ctls, grey dots), asymptomatic viral infection 1638 (Asym, light blue dots), symptomatic viral infection examined in the first 20 days (\leq 20d) or 1639 after 20 days (\geq 20d) of symptoms with those experiencing short term viral RNA shedding

1640 (SVS, orange dots) or long term viral RNA shedding (LVS, purple dots) and RT-qPCR 1641 negative COVID-19 patients in the convalescent phase (Recovery, green dots)). Box plots display a group of numerical data through their 3rd and 1st quartiles (boxe), mean (central 1642 1643 band), minimum and maximum (whiskers). Each dot represents one sample, each patient 1644 being drawn 1-3 times. Statistical analyses used one-way ANOVA with Kenward-Roger method to take into account the number of specimen/patient: p<0.05, p<0.01, p<0.01, p<0.001, 1645 ****p < 0.0001. A. Monocyte subset (A, left panel) defined within the CD45⁺CD3⁻CD56⁻ 1646 CD19⁻CD15⁻ gate, focusing on CD169⁻HLA-DR⁺ in CD16^{low}CD14⁺ classical monocytes 1647 (cMo) (A, middle panel) and CD16⁺CD14^{low} non-classical monocytes (non-cMo) (A, right 1648 1649 panel). B. Neutrophil subset (B, left panel) defined within the CD45⁺CD15⁺ gate, focusing 1650 on CD101, CD10 simple positive or double negative subset (**B**, right panel). C. Transitional B cell subset (CD24⁺CD38^{hi}) in B cells. **D.** Serum titers of anti-S1 RBD IgA (**D. left panel**) 1651 1652 and IgM (D, right panel) in various patient groups at different kinetics. E-I. Temporal 1653 changes of serum concentrations of various soluble factors and their ratios measured in 1654 various phases of COVID-19 presentation.

1655

Figure S5. Non-supervised hierarchical clustering of 33 cancer patients negative for COVID-19 and 21 patients with cancer diagnosed positive for COVID-19 investigated for immunophenotyping and viral parameters within the first 30 days from symptoms onset (or positive RT-qPCR for asymptomatic patients) or COVID-19 negative controls.

1660 The heatmap shows z score-normalized concentration of parameters. Each column represents 1661 a patient and each row a parameter. The color gradient from blue up to red indicates 1662 increasing gradients of concentrations.

1663

Figure S6. Non supervised hierarchical clustering of 29 cancer patients negative for COVID-19 and 35 patients with cancer recovered from COVID-19 investigated for immunophenotyping and viral parameters.

The heatmap shows z score-normalized concentration of parameters. Each column represents a patient and each row a parameter. The color gradient from blue up to red indicates increasing gradients of concentrations. In order to assess the immune characteristics after COVID-19 events in convalescent *vs* controls, we compared only alive patients and we excluded all the dead ones in this analysis.

1673 Figure S7. Lymphoid parameters associated with prolonged viral RNA shedding in 1674 patients with cancer.

1675 Temporal changes and correlation of blood leukocyte parameters measured by high 1676 dimensional spectral flow cytometry in various phases of COVID-19 presentation (no virus 1677 infection (Ctls, grey dots), asymptomatic viral infection (Asym, light blue dots), symptomatic 1678 viral infection examined in the first 20 days (\leq 20d) or after 20 days (>20d) of symptoms with 1679 those experiencing short term viral RNA shedding (SVS, orange dots) or long term viral RNA shedding (LVS, purple dots) and RT-qPCR negative COVID-19 patients in the convalescent 1680 phase (Recovery, green dots)). Box plots display a group of numerical data through their 3rd 1681 1682 and 1st quartiles (box), mean (central band), minimum and maximum (whiskers). Each dot 1683 represents one sample, each patient being drawn 1-3 times. Statistical analyses used one-way 1684 ANOVA with Kenward-Roger method to take into account the number of specimen/patient: *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001. A. Lymphocyte relative proportion within 1685 1686 the CD45⁺ gate, encompassing CD3⁺, CD56⁺ and CD19⁺ cell subsets (A, left panel) with (A, 1687 middle) corresponding to CD19⁺ B cells and (A, right) corresponding to NK cells such as 1688 CD45⁺CD3⁻CD56⁺CD19⁻. B. CD8⁺ T cells (B, left panel) or CD4⁺ T cells (B, right panel) 1689 within the CD45⁺CD3⁺gate. C. Percentages of EM2 defined as CD45RA⁻CD27⁻CD62L⁺ in 1690 $CD8^+$ T cells (**C**, left panel) and subset co-expressing HLA-DR and CD38 in non-naïve CD8⁺

- 1691 (**C, right panel**).
- 1692

Figure S8. Impact of ALC and Ct values in cancer patients survival according to their cancer type (hematological *versus* solid).

Kaplan Meier curve and Cox regression analysis of cancer-related overall survival in patients pooled in the two institutes (Gustave Roussy and Centre Léon Bérard: Cancer_FR1_TR, Cancer_FR1_CR and Cancer_FR3) and in the two surges of the pandemic to analyze the impact of the Absolute Lymphocyte Count (ALC) and Cycle threshold (Ct) at diagnosis in solid tumors only (**A**) (n=177 patients) and hematological tumors only (**B**) (n=49 patients).

1700

Figure S9. Serum metabolome variations in COVID-19 positive cancer patients, according to viral shedding duration, cycle threshold and absolute lymphocyte counts at diagnosis.

1704 Targeted metabolomics analysis was performed on serum samples from confirmed COVID-

1705 19 patients, allowing the identification of significant changes in the relative abundance of 221

1706 metabolites, illustrated by a heatmap. Hierarchical clustering (Euclidean distance, ward

1707 linkage method) of the metabolite abundance is shown, with each row representing a
1708 metabolite and each column corresponding to a different patient. Polyamine derived
1709 metabolites, and bile acids and their conjugates are marked in red.

1710

Figure S10. Lymphopenia and viral shedding are associated with perturbations in polyamine and secondary biliary acid pathways.

1713 A-B. Biliary salt pathway related-metabolites. Mass-spectrometry based abundance of 1714 serum Hyo-(A) and Urso- (B) deoxycholic acid in LVS (purple dots), SVS (orange dots) (left 1715 panel) compared to controls (Ctls) and Spearman correlations with ALC (right panel), color 1716 code corresponds to status for COVID-19 and the category of viral shedding. C-D. 1717 Polyamine pathway-related metabolites. N1-acetylspermidine relative abundance significantly increased in long term viral RNA shedding (LVS, purple dots) regarding 1718 1719 controls (Ctls) (C, left panel) and anticorrelated with ALC (C, right panel), color code 1720 corresponds to the category of Ct and ALC at diagnosis. N1, N12-diacetylspermine relative 1721 abundance significantly increased in critical non-cancer patients (D, left panel) and 1722 anticorrelated with Absolute Lymphocyte Count (ALC) (**D**, right panel). Box plots display a group of numerical data through their 3rd and 1st quartiles (box), mean (central band), 1723 minimum and maximum (whiskers). Each dot represents one sample, each patient being 1724 1725 drawn 1 time for cancer free individuals and 1-2 times for cancer patients. Statistical analyses 1726 used one-way ANOVA with Kenward-Roger method to take into account the number of 1727 specimen/patient (A-B-C left panel): p<0.05, p<0.01, non-parametric unpaired Wilcoxon 1728 test (Mann-Whitney) for each two-group comparison (D left panel): p<0.05, p<0.01, 1729 ****p*< 0.001, *****p*<0.0001.

1730

1731 Supplemental tables

- 1732
- 1733 **Table S1.** Clinical and viral characteristics of patients COVID-19⁺ enrolling in ONCOVID.

1734 Clinical and viral characteristics of patients COVID-19⁺ enrolling in three French COVID-19⁺

and one Canadian cohort according to the duration of viral shedding (SVS vs LVS).

1736

1737 **Table S2.** Clinical characteristics of Cancer_FR1 available for translational research

1739 Supplementary Material, Figures and Tables

1740

Supplementary Material, Figure 1. Strategy of flow cytometry analysis. Briefly, manual gating was performed to extract fcs files of CD45⁺, CD3⁺ T cells and CD19⁺ B cells using the myeloid, T cell and B cell panels, respectively. An example of gating strategy was shown on one sample. Fcs files were compilated in uniform manifold approximation and projection (UMAP) representation. Concatenation of all the samples was shown on the UMAP representation. Relative expression of markers was used to gate the population of interest.

1747

Supplementary Material, Figure 2. Relative expression of principal markers used to gate
the populations explored with the myeloid panel. An example of gating strategy of
monocytes, as well as CD169 and HLA-DR, was shown in one sample.

1751

Supplementary Material, Figure 3. A. Relative expression of principal markers used to gate
the populations explored with the T cell panel (A, top panel). An example of gating strategy
of follicular helper T cells and the activated subset was shown on one sample (A, bottom
panel). B. Relative expression of principal markers used to gate the populations explored with
the B cell panel.

1757

Panel	Fluorochrome	Marker	Manufacturer	Clone	lot number	Target
Myeloid cells/global panel	PE-Cy5	CD10	eBioscience	eBioCB-CALLA	4278756	extra-cellular
	AF6747	CD101	BioLegend	BB27	B221821	extra-cellular
	BV480	CD117	BD	YB5.B8	9186378	extra-cellular
	BV786	CD11b	BD	ICRF44	9294787	extra-cellular
	BV711	CD11c	BD	B-ly6	9169751	extra-cellular
	BV421	CD14	BioLegend	M5E2	B240487	extra-cellular
	BV650	CD141	BD	1A4	9294829	extra-cellular
	Pacific Blue	CD15	BioLegend	W6D3	B210001	extra-cellular
	BUV496	CD16	BD	3G8	7306671	extra-cellular
	PE	CD169	BioLegend	7-239	B279791	extra-cellular
	BUV563	CD19	BD	SJ25C1	9191109	extra-cellular
	BB700	CD3/CD56	BD	SK7/B159	9108776/8319951	extra-cellular
	APC	CD36	BioLegend	5-271	B257710	extra-cellular
	FITC	CD37	BioLegend	B280601	B280601	extra-cellular
	BV605	CD38	BD	HB7	9072931	extra-cellular
	BUV805	CD4	BD	SK3	9136550	extra-cellular
	BUV395	CD45	BD	HI30	9004778	extra-cellular
	PE-Cy7	CD63	BioLegend	H5C6	B257710	extra-cellular
	AF700	CD64	R&D	10.1	1522423	extra-cellular
	BV510	CD8	BD	SK1	9210674	extra-cellular
	PE-Dazzle594	CXCR4	BioLegend	12G5	B257889	extra-cellular
	BUV737	FceRI	BD	AER-37	1043538	extra-cellular
	APC-H7	HLA-DR	BD	G46-6	8318843	extra-cellular
	BV650	CD95	BD	DX2	8155876	extra-cellular
	APC-Cy7	Bcl-6	BD	K112-91	50675	intra-cellular
	PE	Blimp1	R&D system	PRDM1	ACTT0219051	intra-cellular
	BB515	CD127	BD	HIL-7R-M21	6320843	extra-cellular
	BV711	CD16	BioLegend	3G8	B256275	extra-cellular
	APC	CD178/CD95-L	BD	NOK-1	9274343	extra-cellular
_	BV510	CD185/CXCR5	BD	RF8B2	9102753	extra-cellular
ane	BUV395	CD19	BD	SJ25C1	7167875	extra-cellular
T cell panel	PerCp	CD197/CCR7	BioLegend	G043H7	B279387	extra-cellular
	BV785	CD25	BioLegend	BC96	B254092	extra-cellular
	PE-C7	CD27	BD	M-T271	232222	extra-cellular
	BV421	CD279/PD-1	BD	EH12.1	8345993	extra-cellular
	BV480	CD3	BD	UCHT1	7136608	extra-cellular
	BV605	CD38	BD	HIT2	9072931	extra-cellular
	BUV496	CD4	BD	SK3	9080989	extra-cellular
	Krome Orange	CD45	Beckman Coulter	J33	3	extra-cellular

1759 Supplementary Material, Table 2. List of monoclonal antibodies used for the stainings.

	AF700	CD45RA	BD	HI100	9280346	intra-cellular
	BUV661	CD56	BD	NCAM16.2	148111	extra-cellular
-	BV750	CD62L	BD	SK11	160192	extra-cellular
	BUV805	CD8	BD	SK1	126959	extra-cellular
	PE-Cy5.5	Eomes	ThermoFischer	WD1928	2195328	intra-cellular
	FITC	Foxp3	Invitrogen	PCH101	430002	intra-cellular
	BB700	GATA3	BD	L50-823	63599	intra-cellular
-	PE-CF594	Granzyme B	BD	GB11	8165849	intra-cellular
	BUV563	HLA-DR	BD	G46-6	14801	extra-cellular
	BUV737	CD278/ICOS	BD	DX29	154933	extra-cellular
	PerCp-eFluor 710	RORgt	Invitrogen	AFKJS-9	2140726	intra-cellular
	Pacific Blue	T-bet	BioLegend	4B10	B307585	intra-cellular
	AF647	TCF-1	BioLegend	7F11A10	B281714	intra-cellular
	BUV395	CD3	BD	UCHT1	9058566	Extra-cellular
	BUV496	CD38	BD	HIT2	115136	Extra-cellular
	BUV563	CD14	BD	M5E2	9294792	Extra-cellular
	BUV737	CD268	BD	11C1	148102	Extra-cellular
	BUV805	CD45	BD	HI30	8290565	Extra-cellular
	BV421	CD307e/FCRL5	BD	509F6	148106	Extra-cellular
	Pacific Blue	CD11c	Biolegend	3.9	B212042	Extra-cellular
	BV510	CD185/CXCR5	BD	RF8B2	9102753	Extra-cellular
e	BV605	CD267	BD	1A1-K21-M22	148083	Extra-cellular
	BV650	CD24	BD	ML5	9141806	Extra-cellular
cell panel	BV711	CD86	BD	2331	9058846	Extra-cellular
cell	BV785	CD274/PD-L1	BD	MIH1	8262672	Extra-cellular
Ш	BB515	CD95	BD	DX2	9093982	Extra-cellular
	FITC	lgD	BD	IA6-2	6288863	Extra-cellular
	PerCp-Cy5.5	CD279/PD-1	BD	EH12.1	2188652	Extra-cellular
ŀ	PE	CD10	BD	HI10α	9123907	Extra-cellular
	PE-CF594	CD19	BD	HIB19	9128972	Extra-cellular
	PE-Cy7	CD27	BD	M-T271	232222	Extra-cellular
	APC	CD21	BD	B-ly4	52239	Extra-cellular
	AF6747	CD196/CCR6	BD	11A9	12938	Extra-cellular
	APC-R700	CD40	BD	5C3	8819	Extra-cellular
	APC-Vio770	CD20	Miltenyi	REA780	5190430197	Extra-cellular




Figure 1





Figure 2


(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.




Α.

C.

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. B.



(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Figure 6

(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights pseuvery comment allowed without permission.

	, .	Discovery coh	ort anowed wi	•			
Cancer patients' characteris	stics	Cancer_FR1_TR+ Cancer_FR1_CR+ Cancer_FR3 (n=110)	Ct>25 & ALC>800 (n=36)	Ct>25 & ALC<800 (n=22)	Ct<25 & ALC>800 (n=29)	Ct<25 & ALC<800 (n=23)	Ρ
Age (year)	Median (range)	62 (13-95)	62 (13-82)	63 (20-83)	59 (38-95)	60 (21-84)	0.76#
Gender-no(%)	Male	46 (42)	18 (50)	9 (41)	13 (45)	6 (26)	
	Female	64 (58)	18 (50)	13 (59)	16 (55)	17 (74)	0.33
Number of comorbidities	0	38 (45)	10 (45)	5 (34)	10 (38)	13 (62)	
–no(%)°						. ,	
	1	25 (30)	5 (23)	6 (40)	10 (38)	4 (19)	0.26
	2	16 (19)	4 (18)	2 (13)	6 (24)	4 (19)	
	3	5 (6)	3 (14)	2 (13)	0 (0)	0 (0)	
Comorbidities –no(%)°	COPD	6 (7)	2 (9)	1 (7)	1 (4)	2 (10)	
-110(78)	BMI ≥ 30	12 (14)	2 (9)	3 (20)	4 (15)	3 (14)	
	Hypertension	32 (38)	11 (50)	7 (47)	8 (31)	6 (29)	0.98
	Congestive heart failure	3 (6)	1 (5)	1 (7)	1 (4)	0 (0)	
	Diabetes mellitus	10 (12)	3 (14)	1 (7)	4 (15)	2 (10)	
Type of malignancy	S	92 (84)	33 (92)	15 (68)	26 (90)	18 (78)	
–no(%)	H	18 (16)	3 (8)	7 (32)	3 (10)	5 (22)	0.08
Cancer spread	Localized	19 (17)	7 (19)	1 (5)	7 (24)	4 (17)	
-no(%)	Locally advanced	24 (22)	9 (25)	6 (27)	3 (10)	6 (26)	0.46
	Metastatic	24 (22) 67 (61)	9 (25) 20 (56)		19 (66)		0.40
Cancer status	Remission or NED	29 (26)	20 (56) 12 (30)	15 (68) 3 (14)	19 (66) 10 (34)	13 (57) 4 (17)	
-no(%)	SD/PD	47 (43)	12 (30) 17 (47)	3 (14) 11 (50)	10 (34)	4 (17) 8 (35)	0.21
N=-7	Present or PD	34 (31)	7 (19)	8 (36)	8 (28)	11 (48)	0.21
ECOG PS– no(%)	0	28 (25)	13 (36)	5 (23)	5 (18)	5 (22)	
. ,	1	46 (42)	18 (50)	4 (18)	12 (41)	12 (52)	0.01
		• •					0.01
Type of anticancer therapy-	2 or more	36 (33)	5 (14)	13 (59)	12 (41)	6 (26)	
no(%)	None*	53 (48)	20 (56)	8 (36)	14 (48)	10 (43)	0.53
	Chemotherapy	47 (43)	4 (11)	12 (55)	11 (38)	14 (61)	
	Radiotherapy	8 (7)	2 (6)	3 (14)	1 (3)	2 (9)	
	Surgery	8 (7)	3 (8)	2 (9)	3 (10)	0 (0)	0.19
	Hormonal therapy	11 (10)	4 (11)	0	4 (14)	3 (13)	0110
	Immunotherapy	12 (11)	4 (11)	1 (5)	4 (14)	3 (13)	
	Others	11 (10)	2 (6)	2 (9)	0 (0)	5 (22)	
Delay of treatment-no(%)°	Yes (range: 16-170	12 (32)	2 (33)	2 (22)	8 (67)	0 (0)	<0.01
	days)				. ,	()	<0.01
Clinical course	No Day bospital	26 (68)	4 (67)	7 (78)	4 (33)	11 (100)	
–no(%)°	Day hospital	27 (32)	10 (45)	4 (27)	8 (31)	5 (24)	0.63
. ,	Hospitalization	53 (63)	12 (55)	10 (67)	17 (65)	14 (67)	0.03
Death no(%)	Admission to ICU	4 (5)	0	1 (6)	1 (4)	2 (9)	0.02
Death-no(%)	Yes	31 (28)	4 (11)	7 (32)	9 (31)	11 (48)	0.02
		Validation coh		Ct. 05 9	01.05.9	04.05.9	
Cancer patients' characteris	stics	Cancer_FR1_CR+ Cancer FR3	Ct>25 & ALC>800	Ct>25 & ALC<800	Ct<25 & ALC>800	Ct<25 & ALC<800	Р
		(n=116)	(n=22)	(n=27)	(n=29)	(n=38)	•
Age (year)	Median (range)	65 (13-91)	55 (13-86)	64 (46-77)	68 (41-84)	66 (18-91)	0.09#
Gender-no(%)	Male	71 (61)	9 (41)	14 (52)	17 (59)	23 (61)	
	Female	45 (39)	13 (59)	13 (48)	12 (41)	15 (39)	0.48
Type of malignancy	S	85 (73)	19 (86)	19 (70)	22 (76)	25 (66)	
	-	55 (15)			7 (24)	. ,	0.36
	L	24 (07)	2 /1 /	יחניו ט		13 (34)	
-no(%)	H	31 (27)	3 (14)	8 (30)			
–no(%) Cancer spread	Localized	9 (8)	3 (14)	1 (4)	3 (10)	2 (5.3)	
–no(%) Cancer spread	Localized Locally advanced	9 (8) 15 (13)	3 (14) 4 (18)	1 (4) 6 (22)	3 (10) 3 (10)	2 (5.3)	0.40
–no(%) Cancer spread	Localized Locally advanced Metastatic	9 (8) 15 (13) 82 (70)	3 (14) 4 (18) 15 (68)	1 (4) 6 (22) 17 (63)	3 (10)	2 (5.3) 29 (76.4)	0.40
-no(%) Cancer spread -no(%)	Localized Locally advanced	9 (8) 15 (13)	3 (14) 4 (18)	1 (4) 6 (22)	3 (10) 3 (10)	2 (5.3)	0.40
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic	9 (8) 15 (13) 82 (70)	3 (14) 4 (18) 15 (68)	1 (4) 6 (22) 17 (63)	3 (10) 3 (10) 21 (72)	2 (5.3) 29 (76.4)	0.40 0.001
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic Unknown None*	9 (8) 15 (13) 82 (70) 10 (9) 33 (36)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23)	2 (5.3) 29 (76.4) 5 (13) 6 (21)	
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic Unknown None* Chemotherapy	9 (8) 15 (13) 82 (70) 10 (9) 33 (36) 28 (31)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74) 1 (5)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36) 11 (50)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23) 5 (23)	2 (5.3) 29 (76.4) 5 (13) 6 (21) 11 (39)	
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic Unknown None* Chemotherapy Radiotherapy	9 (8) 15 (13) 82 (70) 10 (9) 33 (36) 28 (31) 5 (5)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74) 1 (5) 0 (0)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36) 11 (50) 2 (9)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23) 5 (23) 1 (5)	2 (5.3) 29 (76.4) 5 (13) 6 (21) 11 (39) 2 (7)	
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic Unknown None* Chemotherapy Radiotherapy Surgery	9 (8) 15 (13) 82 (70) 10 (9) 33 (36) 28 (31) 5 (5) 1 (1)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74) 1 (5) 0 (0) 0 (0)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36) 11 (50) 2 (9) 0 (0)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23) 5 (23) 1 (5) 1 (5)	2 (5.3) 29 (76.4) 5 (13) 6 (21) 11 (39) 2 (7) 0 (0)	0.001
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic Unknown None* Chemotherapy Radiotherapy Surgery Hormonal therapy	9 (8) 15 (13) 82 (70) 10 (9) 33 (36) 28 (31) 5 (5) 1 (1) 4 (4)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74) 1 (5) 0 (0) 0 (0) 2 (11)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36) 11 (50) 2 (9) 0 (0) 1 (5)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23) 5 (23) 1 (5) 1 (5) 0 (0)	2 (5.3) 29 (76.4) 5 (13) 6 (21) 11 (39) 2 (7) 0 (0) 1 (4)	
Type of anticancer therapy–no(%)	Localized Locally advanced Metastatic Unknown None* Chemotherapy Radiotherapy Surgery	9 (8) 15 (13) 82 (70) 10 (9) 33 (36) 28 (31) 5 (5) 1 (1)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74) 1 (5) 0 (0) 0 (0)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36) 11 (50) 2 (9) 0 (0)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23) 5 (23) 1 (5) 1 (5)	2 (5.3) 29 (76.4) 5 (13) 6 (21) 11 (39) 2 (7) 0 (0)	0.001
-no(%) Cancer spread -no(%) Type of anticancer therapy-	Localized Locally advanced Metastatic Unknown None* Chemotherapy Radiotherapy Surgery Hormonal therapy	9 (8) 15 (13) 82 (70) 10 (9) 33 (36) 28 (31) 5 (5) 1 (1) 4 (4)	3 (14) 4 (18) 15 (68) 0 (0) 14 (74) 1 (5) 0 (0) 0 (0) 2 (11)	1 (4) 6 (22) 17 (63) 3 (11) 8 (36) 11 (50) 2 (9) 0 (0) 1 (5)	3 (10) 3 (10) 21 (72) 2 (8) 5 (23) 5 (23) 1 (5) 1 (5) 0 (0)	2 (5.3) 29 (76.4) 5 (13) 6 (21) 11 (39) 2 (7) 0 (0) 1 (4)	0.001